<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Egypt Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Egypt Heart J</journal-id><journal-id journal-id-type="pmc-domain-id">3411</journal-id><journal-id journal-id-type="pmc-domain">egypthj</journal-id><journal-title-group><journal-title>The Egyptian Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1110-2608</issn><issn pub-type="epub">2090-911X</issn><publisher><publisher-name>Egyptian Society of Cardiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10149046</article-id><article-id pub-id-type="pmcid-ver">PMC10149046.2</article-id><article-id pub-id-type="pmcaid">10149046</article-id><article-id pub-id-type="pmcaiid">10149434</article-id><article-id pub-id-type="pmid">37120772</article-id><article-id pub-id-type="doi">10.1186/s43044-023-00359-0</article-id><article-id pub-id-type="publisher-id">359</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>COVID-19&#160;HEART unveiling as atrial fibrillation: pathophysiology, management and future directions for research</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0442-1489</contrib-id><name name-style="western"><surname>Kanuri</surname><given-names initials="SH">Sri Harsha</given-names></name><address><email>harsha9009@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jayesh Sirrkay</surname><given-names initials="P">Prapthi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ulucay</surname><given-names initials="AS">Ayse Sena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.67105.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2164 3847</institution-id><institution>Case Western Reserve University, </institution></institution-wrap>Cleveland, OH 44106 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution>University of Minnesota, </institution></institution-wrap>Minneapolis, MN USA </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><volume>75</volume><issue-id pub-id-type="pmc-issue-id">425514</issue-id><elocation-id>36</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-16 21:25:15.423"><day>16</day><month>09</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10149046</article-id><article-id pub-id-type="doi">10.1186/s43044-023-00359-0</article-id><article-version>1</article-version><pub-date><day>30</day><month>04</month><year>2023</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">10149434</article-id><article-id pub-id-type="doi">10.1186/s43044-023-00359-0</article-id><article-version>2</article-version><pub-date><day>30</day><month>04</month><year>2023</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="43044_2023_Article_359.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">COVID-19 infections are known to cause numerous systemic complications including cardiovascular disorders. In this regard, clinicians recently noticed that patients recovering from COVID-19 infections presented with diverse set of cardiovascular disorders in addition to those admitted to ICU (intensive care unit). COVID-19 heart has multifaceted presentation ranging from dysrhythmias, myocarditis, stroke, coronary artery disease, thromboembolism to heart failure. Atrial fibrillation is the most common cardiac arrhythmia among COVID-19 patients. In the background section, we briefly discussed epidemiology and spectrum of cardiac arrhythmias in COVID-19 patients.</p></sec><sec><title>Main body</title><p id="Par2">In this state-of-the-art review we present here, we present the information regarding COVID-19-induced A-fib in sections, namely mechanism of action, clinical presentation, diagnosis and treatment. Unfortunately, its occurrence significantly increases the mortality and morbidity with a potential risk of complications such as cardiac arrest and sudden death. We included separate sections on complications including thromboembolism and ventricular arrhythmias. Since its mechanism is currently a gray area, we included a separate section on basic science research studies that are warranted in the future to comprehend its underlying pathogenic mechanisms.
</p></sec><sec><title>Conclusions</title><p id="Par3">Taken together, this review builds upon the current literature of COVID-19-induced A-fib, including pathophysiology, clinical presentation, treatment and complications. Furthermore, it provides recommendations for future research moving forward that can open avenues for developing novel remedies that can prevent as well as hasten clinical recovery of atrial fibrillation in COVID-19 patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s43044-023-00359-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Atrial fibrillation</kwd><kwd>Arrhythmias</kwd><kwd>Atrial reentry</kwd><kwd>Atrial premature beats</kwd><kwd>Atrial substrate</kwd><kwd>Automaticity</kwd><kwd>Inflammation</kwd><kwd>Cytokine storm</kwd><kwd>Oxidative stress</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><sec id="Sec2"><title>Introduction</title><p id="Par61">There has been an uptick in the occurrence of atrial fibrillation (A-fib) cases in COVID-19 patients during the recently concluded pandemic. Out of 9574 patients, COVID-19 patients admitted to ICU in Northwell Health System in New York, A-fib developed in 1687 (17.6%) of them and these patients experienced significantly higher in-hospital mortality compared to those with sinus rhythm (55.2% vs 46.8%) [<xref ref-type="bibr" rid="CR1">1</xref>]. In a retrospective cohort study, it was revealed that the odd ratio of developing A-fib in COVID-19-positive patients is higher than that in COVID-19-negative patients (1.19 95%:1.00, 2.41) and pre-pandemic patients (1.57 95% CI (confidence interval):1.23, 2.00) [<xref ref-type="bibr" rid="CR2">2</xref>]. It is well known that cardiovascular risk factors such as high blood pressure, diabetes and obesity increase the propensity to develop atrial fibrillation [<xref ref-type="bibr" rid="CR3">3</xref>]. Clinicians witnessed the increased risk for developing of cardiac arrhythmias in COVID-19 patients and this propensity increases substantially in those with higher CHA(2)DS2-VASc score [<xref ref-type="bibr" rid="CR4">4</xref>]. These findings highlight the fact that the viral infection can alone function as an independent risk factor for developing cardiac arrhythmias and associated worse clinical outcomes. The ability of COVID-19 virus to provoke a wide variety of cardiac arrhythmias had baffled and perplexed the entire clinical and research community. Analysis of cardiovascular outcomes in 153,760 older while male patients utilizing US Veteran Health System from March 1, 2020, to January 15, 2021, revealed 19.86 incidents of dysrhythmias, 10.74 incidents of atrial fibrillation, 23.48 incidents of Major Adverse Cardiovascular Events (MACE) and 4.03 incidents of stroke for every 1000 patients with COVID-19 diagnosis [<xref ref-type="bibr" rid="CR5">5</xref>]. The precise etiology for occurrence of atrial fibrillation in COVID-19 patients is currently obscure. Even though there is dearth of research studies in this regard, some researchers tried to implicate cytokine storm, NLRP3 inflammasome, hypoxemia, endothelial dysfunction, electrolyte disturbances, microvascular inflammation, platelet activation, fibrin deposition and activation of sympathetic nervous system for inciting atrial fibrillation in COVID-19 patients [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Since this is relatively a new clinical phenomenon, improved understanding of crucial etiological factors and their interplay at the cellular level particularly in atrial cardiomyocytes, endothelial cells and pericytes would yield valuable information regarding the probable pathophysiological mechanisms leading to generation of atrial substrate. Moreover, the clinical presentation of A-Fib is very vague and clinicians managing in COVID-19 patients admitted to ICU should be more vigilant for this clinical entity. This is very critical because it usually requires prompt diagnosis and management for preventing poor cardiovascular outcomes and its associated complications. It is important to understand that COVID-19 and A-fib is a lethal combination because they together increase the risk of pulmonary embolism, stroke and venous thromboembolism [<xref ref-type="bibr" rid="CR7">7</xref>]. Sometimes, it is quite possible atrial fibrillation in COVID-19 patients can degenerate into ventricular fibrillation and eventually cause cardiac arrest and sudden death. In this review, which is presented we summarized the epidemiology, pathophysiological mechanisms, clinical symptomatology, diagnosis, therapeutic options and complications of COVID-19-induced A-fib. Furthermore, we discussed extensively the scope of future research that can be performed in the cell culture and animal models for unraveling the potential mechanisms for generation of atrial substrate, which can induce atrial fibrillation in COVID-19 patients. We hope that this review will fill the knowledge gap in understanding of pathophysiological mechanisms of COVID-19-induced atrial fibrillation and would jumpstart basic science and clinical research studies in this regard. Any useful preliminary information gleaned from these studies can be exploited for drafting novel therapeutic modalities for decreasing mortality and morbidity of this clinical entity.</p></sec><sec id="Sec3"><title>The spectrum of cardiac arrhythmias in COVID-19 patients admitted to hospital</title><p id="Par62">The prevalence of arrhythmias in COVID-19 patients admitted to the hospital is around 18% and 15% during admission and discharge, respectively [<xref ref-type="bibr" rid="CR8">8</xref>]. The incidence of ECG abnormalities in COVID-19 patients includes sinus tachycardia (85.5%), atrial fibrillation (10.5%), atrial block (2%), atrial flutter (1%) and junctional rhythm (0.5%) [<xref ref-type="bibr" rid="CR8">8</xref>]. An observational study conducted on COVID-19 patients admitted to the hospital revealed the incidence of arrhythmias as follows; premature ventricular complexes (28.7%), non-sustained ventricular tachycardia (15.4%), sustained ventricular tachycardia (1.4%) and ventricular fibrillation (0.7%) [<xref ref-type="bibr" rid="CR9">9</xref>]. In this observational study, the overall mortality of COVID-19 patients which were followed up for 23&#160;days was approximately 25% [<xref ref-type="bibr" rid="CR9">9</xref>]. The spectrum of arrhythmias in 700 COVID-19 patients admitted to a hospital and serially followed up for 2.5&#160;months, include cardiac arrest (9), atrial fibrillation (25), clinically significant bradyarrhythmias (9), non-sustained ventricular tachycardia (NSVT) (10) [<xref ref-type="bibr" rid="CR10">10</xref>]. In this previous study, the in-hospital mortality was highest in the patients developing cardiac arrest (OR 20.47; 95% CI 5.19&#8211;80.69) followed by atrial fibrillation (OR 6.73; 95% CI 2.52&#8211;17.98) [<xref ref-type="bibr" rid="CR10">10</xref>]. Overall prevalence of atrial fibrillation in patients with COVID-19 without and with previous history of cardiovascular diseases is around 19&#8211;21% and 36%, respectively [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec4"><title>Epidemiology of COVID-19-induced atrial fibrillation</title><p id="Par63">Atrial fibrillation is the most common cardiac arrhythmia in COVID-19 patients. The incidence of A-fib in COVID-19 patients without and with cardiovascular abnormalities is approximately 19&#8211;21% and 36%, respectively [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The incidence tends to be even higher (23&#8211;33%) in critically ill COVID-19 with ARDS (Acute Respiratory Distress Syndrome) or sepsis admitted ICU (Intensive Care Unit) [<xref ref-type="bibr" rid="CR6">6</xref>]. Out of 30,999 COVID-19 patients admitted to 120 medical institutions in USA, A-fib developed approximately 1517 patients (5.4%) who have associated cardiovascular risk factors [<xref ref-type="bibr" rid="CR3">3</xref>]. Retrospective analysis of 78,725 COVID-19 patients with comorbidities in Mass General Brigham Health System revealed that the odds of developing A-fib is 1.18 times in COVID-19 patients compared to non-COVID-19 patients [<xref ref-type="bibr" rid="CR2">2</xref>]. Meta-analysis of studies performed until February 2021 to assess the prevalence of A-fib in COVID-19 patients demonstrated that it is 2.5 times more common older population (&gt;&#8201;60&#160;years) compared to younger population [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par64">Demographically, the incidence of A-fib is more common in Europeans (15%) followed by Americans (11%), Asians (6%) and Africans (2%) in COVID-19 patients [<xref ref-type="bibr" rid="CR12">12</xref>]. Retrospective analysis of 3970 COVID-19 patients diagnosed between February 4 to April 22, 2020, indicated that the prevalence of A-Fib is 10% and 4% in COVID-19 patients with and without history of atrial arrhythmias, respectively [<xref ref-type="bibr" rid="CR13">13</xref>]. Another retrospective analysis of aged population (&gt;&#8201;60&#160;years) from multicenter registry of Italian and Norwegian societies of Gerontology and Geriatrics unveiled that the incidence of A-fib is around 21.8% and it more prevalent in those with higher CHA<sub>2</sub>DS<sub>2</sub>-VASc score [<xref ref-type="bibr" rid="CR14">14</xref>]. Multicenter cohort study of COVID-19 patients diagnosed with PCR from March 2020 to December 2021 from 17 hospitals affiliated with University of California indicated that the risk of A-fib (10.85%) is lower in COVID-19 patients than in non-COVID-19 patients (14.16%) [<xref ref-type="bibr" rid="CR15">15</xref>]. Single-center retrospective analysis of 492 patients admitted to Bahrain Defense Force COVID-19 ICU from April 2020 to December 2020 revealed higher risk of developing A-fib in COVID-19 group (66.7%) compared to control group (17.1%) [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec></sec><sec id="Sec5"><title>Main text</title><sec id="Sec6"><title>Underlying mechanisms hypothesized for occurrence of COVID-19-induced A-fib</title><p id="Par65">Although atrial fibrillation is one of the most common arrhythmias in COVID-19 patients, its exact mechanism is not elucidated definitely yet. Nevertheless, researchers hypothesized some speculative mechanisms for its occurrence which can be summarized as downregulation of angiotensin-converting enzyme 2 (ACE2), CD-147, sialic acid-spike protein interaction, cytokine storm, endothelial damage, electrolyte disturbances, hypoxemia and hyperactive sympathetic nervous system [<xref ref-type="bibr" rid="CR6">6</xref>]. Loss of surface ACE2 from atrial myocytes and vascular endothelial cells due to its internalization secondary to COVID-19 binding causes deprivation of its protective effect resulting in various cellular alterations such as hypertrophy, increased vascular permeability, endothelial dysfunction, inflammation, and fibrosis. COVID-19-induced myocardial inflammation is a clinical entity that has been widely documented in previous studies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. This myocardial inflammation can entail activation of downstream signaling pathways (STAT3/Rac3/Angiotensin-II) which would provide basis for increased collagen synthesis, atrial fibrosis, structural remodeling and atrial substrate formation for subsequent development of atrial fibrillation [<xref ref-type="bibr" rid="CR19">19</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Pulmonary thromboembolism and pulmonary hypertension are well known reported complications of COVID-19 patients [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. These clinical abnormalities provoke several pathological derangements ranging from accentuated intra-atrial pressures, elevated right ventricular afterload, increased myocardial oxygen demand, hypoxia, and massive atrial dilation all of which in combination increase the risk for developing atrial fibrillation [<xref ref-type="bibr" rid="CR22">22</xref>] (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Extracardiac factors that are implicated in manifestation of Atrial Fibrillation in COVID-19 patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="43044_2023_359_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Cardio-pulmonery effects of COVID-19 underlying the development of Atrial Fibrillation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="43044_2023_359_Fig2_HTML.jpg"/></fig></p><p id="Par66">Upon entering into the atrial myocytes, it undergoes replication and provokes multifarious pathological derangements that underlie the susceptibility to cardiac arrhythmias. First, it can impair the intercellular communication between adjacent cardiomyocytes by downregulating the expression of connexins (Cx40 and Cx43), thus leading to derailed impulse conduction and protracted cardiac cycle duration [<xref ref-type="bibr" rid="CR23">23</xref>]. Second, it can cause wreckage in the functioning of intracellular calcium handling proteins such as ryanodine receptors (RyR), sarco-endoplasmic reticulum calcium ATPase (SERCA) and phospholamban (PLB) leading to increased calcium release and intracellular calcium accumulation [<xref ref-type="bibr" rid="CR23">23</xref>]. Third, it can facilitate inward depolarizing (<italic toggle="yes">I</italic><sub>CaL</sub>,&#160;<italic toggle="yes">I</italic><sub>Na</sub>) currents and the same time antagonism of outward repolarizing currents (<italic toggle="yes">I</italic><sub>to</sub>,&#160;<italic toggle="yes">I</italic><sub>Ks</sub>,&#160;<italic toggle="yes">I</italic><sub>Kr</sub>). Fourth, direct invasion of cardiomyocytes can also lead to myocardial inflammation due to combined effect of inflammatory infiltrate, immune response and cytokines [<xref ref-type="bibr" rid="CR23">23</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Lastly, viral involvement of neighboring cardiac fibroblasts can lead to activation of fibrogenic pathways, extracellular matrix formation and deposition of fibrogenic tissue in the atrial myocardium [<xref ref-type="bibr" rid="CR23">23</xref>]. These pathological derangements cultivate a viable breeding ground for initiation and sustaining of atrial fibrillation in COVID-19 patients.</p><p id="Par67">Due to disturbance of the delicate balance between Th1 and Th2 lymphocytes, cytokine storm is unleashed with production of pro-inflammatory cytokines takes place [<xref ref-type="bibr" rid="CR6">6</xref>]. Systemic inflammatory response syndrome along with upregulation of cytokines such as IL-6, TNF and IL-1 can be responsible for prolongation of ventricular action potential [<xref ref-type="bibr" rid="CR24">24</xref>]. These cytokine induced cellular events in atrial myocytes can incite atrial fibrillation. One the important mechanisms suggested for cytokine induced atrial fibrillation include increased intracellular calcium overload and elevated <italic toggle="yes">I</italic><sub>cal</sub> (L-type calcium current) [<xref ref-type="bibr" rid="CR23">23</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Furthermore, oxidative stress secondary to inflammation within the atrial myocyte can be responsible for initiating and sustaining atrial fibrillation. Sustained inflammatory state in COVID-19-induced atrial fibrillation documented by marked upregulation of IL-6, CRP (C-reactive protein) and plasma viscosity provides a forewarning for occurrence of thromboembolism and stroke in these patients [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par68">Electrolyte disturbances (hypokalemia, hyponatremia and hypocalcemia) are considered as one of the most important risk factors for development of tachyarrhythmias including atrial fibrillation [<xref ref-type="bibr" rid="CR27">27</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The occurrence of electrolyte disturbances in COVID-19 patients is explained by acute renal failure, gastrointestinal disturbances, activation of renin angiotensin system and inflammation [<xref ref-type="bibr" rid="CR22">22</xref>]. Hyponatremia and hypokalemia tend to induce atrial fibrillation via altering the electrophysiological properties of sino-atrial node (decreased beating rate) and pulmonary vein (attenuated burst firing) [<xref ref-type="bibr" rid="CR28">28</xref>]. Hypokalemia leads to increased atrial arrhythmogenic potential due to sway on resting membrane potential with changes ranging from fastened depolarization, predominance of hyperpolarization state to increased atrial resting membrane potential [<xref ref-type="bibr" rid="CR27">27</xref>]. These atrial cellular changes leads to incitement of ectopic beats and reentry phenomenon, which combined increases the propensity to develop atrial fibrillation [<xref ref-type="bibr" rid="CR27">27</xref>]. Hypocalcemia induced atrial fibrillation can be attributed to structural changes, alteration of calcium cycling and revamping the electrical activity [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par69">QT prolongation which can be due to virus itself or due to administration of QTc prolonging drugs for managing these patients can be a likely predisposing factor for initiation of cardiac arrhythmias in these patients [<xref ref-type="bibr" rid="CR24">24</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). COVID-19 virus might alter the metabolizing activity of the liver enzymes (cytochrome P450), thereby increasing the half-life of QT prolonging drugs that are currently administered to these patients [<xref ref-type="bibr" rid="CR23">23</xref>]. Studies have shown that patients with long QT interval syndrome have an increasing proclivity to develop atrial fibrillation [<xref ref-type="bibr" rid="CR29">29</xref>]. Increased propensity of atrial fibrillation in long QT interval syndrome might be secondary to prolonged atrial muscle refractoriness, delayed sodium entry into atrial myocytes, increased intracellular calcium load and automaticity [<xref ref-type="bibr" rid="CR30">30</xref>]. These cellular abnormalities can pave the way for occurrence of atrial torsades de pointes (polymorphic atrial tachycardia with undulating P-wave) which has the potential to degenerate into atrial fibrillation [<xref ref-type="bibr" rid="CR30">30</xref>]. Antimalarial (Chloroquine) and anti-viral (Ritonavir) drugs usually prescribed for managing COVID-19 infections indirectly prolong the half-life of QT prolonging drugs via inhibition of cytochrome P450 2D6 enzymes in the hepatic tissues [<xref ref-type="bibr" rid="CR31">31</xref>]. These QT prolonging drugs might also have a collateral effect of attenuating HERG K<sup>+</sup> channels, thereby resulting in lengthening of ventricular depolarization [<xref ref-type="bibr" rid="CR31">31</xref>]. QT prolongation is associated with systemic inflammatory response characterized by IL-6 upregulation and administration of IL-6 receptor blocking antibody (Tocilizumab) had yielded successful outcomes in decreasing the risk of QT interval related tachyarrhythmias including atrial fibrillation [<xref ref-type="bibr" rid="CR31">31</xref>]. Furthermore, among patients with atrial fibrillation who underwent catheter ablation, the presence of longer QTc can be regarded as an independent risk for developing future stroke and heart failure [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par70">COVID-19-induced kick starting of central inflammatory reflexes and peripheral stellation ganglia activation can provoke increased sympathetic outflow to the atrial myocardium [<xref ref-type="bibr" rid="CR23">23</xref>]. Enhanced sympathetic outflow leads to early after-depolarization (EAD), delayed after-depolarization (DAD) and enhanced automaticity, thereby increasing the ectopic activity in atrial myocytes [<xref ref-type="bibr" rid="CR33">33</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The other mechanisms proposed for establishment of A-fib substrate with sympathetic stimulation include calcium overload, over expression of hypertrophic and pro-fibrotic genes, larger window currents, augmentation of slow delayed-rectifier K<sup>+</sup>-current (<italic toggle="yes">I</italic><sub>Ks</sub>) and attenuation of inward-rectifier K<sup>+</sup>-current (<italic toggle="yes">I</italic><sub>K1</sub>) [<xref ref-type="bibr" rid="CR33">33</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Moreover, increased expression of fibrogenic genes would probably lead to excess deposition of fibrous tissue resulting in segregation of adjacent atrial myocytes [<xref ref-type="bibr" rid="CR19">19</xref>]. This uncoupling of atrial myocytes would cause inter-atrial conduction disturbances, thus providing a hotbed for subsequent development of atrial fibrillation [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec7"><title>How about the cellular mechanisms for A-fib from other inflammatory involvement of heart muscle in general (e.g., viral, pneumonia or autoimmune)</title><p id="Par71">Major aberrations instigated by viral infections that predispose to occurrence of A-fib can be classified into impairment of atrial electrophysiology and structural remodeling [<xref ref-type="bibr" rid="CR34">34</xref>]. In this regard, atrial fibrosis, action potential shortening, breakdown of intercellular connections and alteration of calcium handling are speculated to be important changes that are operational for inciting atrial fibrillation. Initiation, maintenance and recurrence of A-fib with viral and systemic inflammatory diseases can be associated with presence of significant biomarkers in the blood such as MCP-1 (Monocyte chemoattractant protein-1), NLRP3 and pro-inflammatory markers (IL-1, IL-2, IL-6, IL-8 and IL-12 [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par72">In nonvalvular A-fib secondary to infectious inflammatory etiology, researchers demonstrated higher levels of TLR-2 (Toll-like receptor-2) receptors and IL-6 compared to those with sinus rhythm [<xref ref-type="bibr" rid="CR35">35</xref>]. Influenza infection increases the risk of developing A-fib and flu vaccination tend to downregulate this risk by 18% [<xref ref-type="bibr" rid="CR36">36</xref>]. Influenza seems to incite A-fib through direct cardiomyocyte invasion, pro-inflammatory cytokine production and increased sympathetic tone, all of which are instrumental in instigating electrophysical changes necessary for generating arrhythmogenic foci [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Influenza A virus infected hearts exhibit altered cardiac proteome which specifies high stress and low energy state [<xref ref-type="bibr" rid="CR38">38</xref>]. Cardiomyocytes infected with influenza A virus demonstrated oxidative stress, mitochondrial damage, decreased phosphorylation, necroptosis and cell death [<xref ref-type="bibr" rid="CR38">38</xref>]. Community acquired pneumonia tend to cause A-fib through multiple mechanisms including prothrombotic state, myocardial injury, myocardial ischemia, sepsis, pericarditis, myocarditis, impaired gas exchange and disorganized sympathetic&#8211;vagal balance [<xref ref-type="bibr" rid="CR39">39</xref>]. In patients with gingivitis, oral bacteria tend to be arrhythmogenic through various pathways ranging from secretion of inflammatory mediators, molecular mimicry, overactivation of autonomic nervous system, direct invasion to secretion of bacterial toxins [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par73">Autoimmunity favors the production of auto-antibodies against myosin, M2 receptors, Na+/K+ pump, heat shock proteins and &#946;-adrenergic receptors [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. These immune complexes in the atrial myocardium will subsequently prime the atrial myocardium to become a fertile ground for generation of A-fib [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Moreover, autoimmune vasculitis characterized by inflammation and fibrinoid necrosis of vessel walls occurs globally in all the systemic tissues, a critical factor implicated in the pathogenesis of atrial fibrillation [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec8"><title>Risk factors</title><p id="Par74">Previous studies had shown that AF is more likely to develop in COVID-19 patients compared to non-COVID-19 patients (Odds&#8201;&gt;&#8201;1.19) and pre-pandemic patients (Odds&#8201;&gt;&#8201;1.57) [<xref ref-type="bibr" rid="CR2">2</xref>]. Some of the risk factors that are hypothesized for increasing the propensity of developing atrial fibrillation in COVID-19 patients include mitral valve disease, heart failure, history of myocardial infarction, renal failure, COPD, obesity, diabetes, hypertension, peripheral vascular disease, hyperlipidemia, smoking and history of stroke [<xref ref-type="bibr" rid="CR2">2</xref>]. In COVID-19 patients admitted for hospital due to the presence of comorbidities, the risk of developing AF is higher with the presence of in-hospital events such as ICU admission (64.5%), mechanical ventilation (MV) (47.6%), MV with mechanical circulatory support (7.7%), MV with vasopressors (31.8%), cardiac arrest (9.8%), myocardial infarction (13.8%), deep vein thrombosis (8.2%), stroke (4.4%), clinically significant bleeding (9%), corticosteroids (60.2%), renal replacement therapy (13.1%) and remdesivir (13.3%) [<xref ref-type="bibr" rid="CR3">3</xref>]. The presence of other risk factors such as acute respiratory distress and sepsis is bound to accentuate the tendency to develop by AF by 12&#8211;20% [<xref ref-type="bibr" rid="CR3">3</xref>]. Severe COVID-19 patients who are admitted to ICU are more to develop hypotension, hypoxia, and elevated pressures in right and left cardiac chambers that increases the predilection for having AF. Studies demonstrate AF is less likely to develop in black patients compared to non-Hispanic whites even though they tend to have more cardiovascular risk factors such as diabetes, hypertension and obesity [<xref ref-type="bibr" rid="CR3">3</xref>]. Gender differences were noted with males tend to have to more proclivity to develop AF compared to females which can be partially explained by effect of male hormones, adipose tissue and body mass index [<xref ref-type="bibr" rid="CR3">3</xref>].</p></sec><sec id="Sec100"><title>Summary of Clinical cases reported for COVID-19-induced A-fib</title><p id="Par75">The clinical presentation of atrial fibrillation can be varied with non-specific signs and symptoms. The following table enumerates the age, clinical symptoms, signs, diagnostic tests, treatment and prognosis in patients presenting with COVID-19-induced atrial fibrillation.</p><p id="Par76">Atrial fibrillation (A-fib) is characterized by an irregular and rapid heart rate, which can lead to various symptoms and complications. Case studies suggest that the most common symptoms observed among A-fib patients were palpitations, shortness of breath, and fatigue. Many patients also presented with altered mental status that could be a result of the atrial fibrillation. Other less frequently reported symptoms included dizziness, chest pain and syncope. Patients often presented with elevated heart rates (mean of 120&#160;bpm) and irregular rhythms on physical examination. EKG results showed consistent evidence of A-fib in all cases, with some patients also exhibiting additional abnormalities such as atrial flutter, ST-T wave changes and ventricular ectopy.<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Cases</th><th align="left" colspan="1" rowspan="1">Demographics</th><th align="left" colspan="1" rowspan="1">Clinical symptoms</th><th align="left" colspan="1" rowspan="1">Signs</th><th align="left" colspan="1" rowspan="1">Diagnostic tests</th><th align="left" colspan="1" rowspan="1">Treatment and prognosis</th><th align="left" colspan="1" rowspan="1">Prognosis</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"><p>73-year-old female</p><p>Caucasian</p></td><td align="left" colspan="1" rowspan="1">Altered mental status, panic attack with palpitations, nausea, numbness, tachypnea, heavy breathing, dry cough, and chest discomfort</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 137/71</p><p><bold>O2 sat</bold> 83%</p><p><bold>Tem</bold>:99.7&#176;F</p><p><bold>HR</bold>&#8201;~&#8201;115</p><p><bold>RR</bold>&#8201;~&#8201;33</p><p>Tachycardia,</p><p>Irregular rhythm</p><p>Pulse deficit</p><p>Bibasilar crackles</p></td><td align="left" colspan="1" rowspan="1"><p><bold>CXR</bold>: Diffuse pulmonary edema, bilateral interstitial infiltrates, and hazy opacities</p><p><bold>ECG</bold>: atrial fibrillation with RVR</p><p><bold>CT Scan</bold>: multiple ground glass opacities predominantly in peripherally and posteriorly</p></td><td align="left" colspan="1" rowspan="1">Supportive care, Dexamethasone, Hydroxychloroquine, Remdesivir, Anticoagulation, azithromycin</td><td align="left" colspan="1" rowspan="1">Clinical recovery to sinus rhythm</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">66-year-old female</td><td align="left" colspan="1" rowspan="1">On 6th day of COVID-19 related admission patient presented with tachycardia and palpitations</td><td align="left" colspan="1" rowspan="1"><bold>HR</bold>: 160&#160;bpm</td><td align="left" colspan="1" rowspan="1"><bold>EKG</bold> showed atrial fibrillation with rapid ventricular response</td><td align="left" colspan="1" rowspan="1"><p>Metoprolol</p><p>Diltiazem</p><p>Carvedilol</p></td><td align="left" colspan="1" rowspan="1">Clinical recovery to sinus rhythm</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">66-year-old male</td><td align="left" colspan="1" rowspan="1">Sudden onset of palpitations and worsening dyspnea</td><td align="left" colspan="1" rowspan="1"><p><bold>HR</bold>: 186</p><p><bold>BP</bold>: 134/80</p></td><td align="left" colspan="1" rowspan="1"><bold>EKG</bold> showed irregular, narrow-QRS complex tachycardia without P waves</td><td align="left" colspan="1" rowspan="1"><p>Amiodarone</p><p>External Electric shock 260&#160;J</p></td><td align="left" colspan="1" rowspan="1">Brainstem acute ischemic stroke, ventricular fibrillation and cardiac arrest</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">90-year-old African American female</td><td align="left" colspan="1" rowspan="1">Altered mental status from welfare check</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 141/78</p><p><bold>Tem</bold>:97.9&#176;F</p><p><bold>HR</bold>&#8201;~&#8201;140</p><p><bold>RR</bold>&#8201;~&#8201;44</p></td><td align="left" colspan="1" rowspan="1"><p><bold>ECG</bold>: atrial fibrillation with RVR</p><p>Echo: Ejection fraction 65&#8211;70% with grade I diastolic dysfunction</p></td><td align="left" colspan="1" rowspan="1"><p>Intubation, supportive care, Hydroxychloroquine</p><p>azithromycin</p></td><td align="left" colspan="1" rowspan="1">Clinical recovery to sinus rhythm</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">50-year-old male</td><td align="left" colspan="1" rowspan="1">Pain on the posterior aspect of the right lower leg</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 129/76</p><p><bold>Tem</bold>:98.9&#176;F</p><p><bold>HR</bold>&#8201;~&#8201;78</p><p><bold>RR</bold>&#8201;~&#8201;18</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG</bold> showed irregular heart rate with new-onset AF</p><p><bold>CT scan extremities</bold>: partial right popliteal block</p><p><bold>CT abdomen</bold>: Left kidney lower pole infarction</p><p><bold>MRA</bold>: Right occipital lobe subacute infarcts</p></td><td align="left" colspan="1" rowspan="1"><p>Inpatient: Azithromycin, oseltamivir, paracetamol, Vitamin C, zinc sulfate, Hydroxychloroquine</p><p>Bisoprolol and Omeprazole. Outpatient: Direct acting oral anticoagulant (DOAC), atorvastatin, aspirin and bisoprolol</p><p>Follow-up with AF clinic for electric cardioversion</p></td><td align="left" colspan="1" rowspan="1">Clinical recovery to sinus rhythm</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">72-year-old female</td><td align="left" colspan="1" rowspan="1">Altered mental status</td><td align="left" colspan="1" rowspan="1"><p><bold>HR</bold>&#8201;~&#8201;133</p><p>Tachypnea</p><p>Leukocytosis</p><p>Increased lactate</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG</bold> New-onset AF with RVR</p><p><bold>Troponins</bold>:&#8201;&gt;&#8201;20,000&#160;ng without ST and T elevations suggesting acute cardiac ischemia</p></td><td align="left" colspan="1" rowspan="1">Cardizem drip followed by oral amiodarone and metoprolol</td><td align="left" colspan="1" rowspan="1">Clinical recovery to sinus rhythm</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">57-year-old male</td><td align="left" colspan="1" rowspan="1">Palpitations and progressive dyspnea</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 117/97</p><p><bold>O2 sat</bold> 97%</p><p><bold>HR</bold>&#8201;~&#8201;152</p><p><bold>RR</bold>&#8201;~&#8201;14</p><p>Irregularly irregular puse</p><p>Bibasilar fine crepitations</p><p>Elevated JVP</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG</bold> New-onset AF</p><p>Echo: LVEF 20% and MR</p><p>Cardiac MRI: biventricular edema, dysfunction with LVEF 30%. Severe myocarditis</p></td><td align="left" colspan="1" rowspan="1">Intravenous diuretics, rate control agents, anticoagulation, ACE inhibitor and mineralocorticoid</td><td align="left" colspan="1" rowspan="1">Clinical recovery. Cardiac MRI at 3-month interval planned with outpatient follow-up</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">78-year-old Caucasian male</td><td align="left" colspan="1" rowspan="1">Altered mental status, panic attack, palpitations, nausea, numbness, tachypnea, heavy breathing, dry cough and chest discomfort</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 137/71</p><p><bold>O2 sat</bold> 83%</p><p><bold>Temp</bold> 39.7C</p><p><bold>HR</bold>&#8201;~&#8201;115</p><p><bold>RR</bold>&#8201;~&#8201;33</p><p>Irregular rhythm</p><p>Bibasilar crackles</p><p>Pulse deficit</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG</bold> AF with RVR</p><p><bold>Anion gap</bold>: abnormal</p><p>Metabolic alkalosis</p><p>Echo: borderline abnormal LVEF (50&#8211;55%), LV diastolic dysfunction, mild pericardial effusion, moderate septal hypertrophy, mild dilated LV (LVEDD: 58.9&#160;mm and LVESD: 40.7&#160;mm) and restrictive LV filling pattern</p></td><td align="left" colspan="1" rowspan="1">ICU admission, intubation, vasopressor, supportive care, dexamethasone, hydroxychloroquine, remdesevir, IV Ibutilide, anticoagulation and azithromycin</td><td align="left" colspan="1" rowspan="1">Normal sinus rhythm was restored two days prior to extubation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">72-year-old male</td><td align="left" colspan="1" rowspan="1">Severely hypoxic patient (Sp02 65%)</td><td align="left" colspan="1" rowspan="1">Irregular heart rhythm, exhausted, perspiring, bilateral medium crackles,</td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> AF</p><p><bold>Echo</bold>: Globally reduced LV systolic function, EF 30%</p></td><td align="left" colspan="1" rowspan="1">Intubation, Non-adrenaline, Dobutamine, Volume resuscitation, Argipressin, Dexamethasone, Landiolol, amiodarone, digitoxin, ivabradine and Levosimandan</td><td align="left" colspan="1" rowspan="1"><p>Pericardial tamponade</p><p>Cardiogenic shock</p><p>Death</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">18 y male</td><td align="left" colspan="1" rowspan="1">Refractory hypotension, blurry vision, eye redness, nausea, vomiting, cheat pain, nausea, vomiting, syncope, dizziness and refractory hypotension</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 80/40</p><p><bold>HR</bold>&#8201;~&#8201;120</p><p>Hepatomegaly</p><p>Injected conjunctiva</p><p>Erythematous tongue</p><p>Blanching rash on palm and wrists</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> AF, wide complex tachycardia</p><p><bold>Echo</bold>: mild pericardial effusion</p></td><td align="left" colspan="1" rowspan="1"><p>Cardioversion 100&#8211;150&#160;J</p><p>Bolus of Amiodarone</p><p>Low dose epinephrine</p></td><td align="left" colspan="1" rowspan="1">Normal sinus rhythm is restored with complete clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">15-year-old African American female</td><td align="left" colspan="1" rowspan="1">Headache, vomiting and fatigue</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 70/90</p><p><bold>Temp</bold> 102.8 F</p><p><bold>HR</bold>&#8201;~&#8201;150</p></td><td align="left" colspan="1" rowspan="1"><p><bold>Echo:</bold> Severe LV dysfunction without atrial or ventricular dilation</p><p><bold>EKG</bold>: AF with RVR</p></td><td align="left" colspan="1" rowspan="1">IV saline, milrinone, epinephrine, IV immunoglobulin, IV methyl prednisolone, subcutaneous LMW heparin, IL-1 receptor antagonist (Anakinra). Cardioversion (50&#160;J) and Amiodarone</td><td align="left" colspan="1" rowspan="1">Normal sinus rhythm is restored with complete clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par77">
<table-wrap id="Tabb" position="float" orientation="portrait"><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Demographics</th><th align="left" colspan="1" rowspan="1">Clinical symptoms</th><th align="left" colspan="1" rowspan="1">Signs</th><th align="left" colspan="1" rowspan="1">Diagnostic tests</th><th align="left" colspan="1" rowspan="1">Treatment and prognosis</th><th align="left" colspan="1" rowspan="1">Prognosis</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">66-year-old female</td><td align="left" colspan="1" rowspan="1">COVID-19 patient presented with tachycardia and palpitations on the 6th day of admission</td><td align="left" colspan="1" rowspan="1"><bold>HR</bold>: 175&#160;bpm</td><td align="left" colspan="1" rowspan="1"><p><bold>EKG</bold>: Irregularly irregular rhythm with absence of P waves</p><p>AF with RVR</p><p>Echo: Preserved ventricular fraction with no other abnormality</p></td><td align="left" colspan="1" rowspan="1">IV Metroprolol, IV diltiazem and Carvedilol 30&#160;mg every 6&#160;h</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">84-year-old male</td><td align="left" colspan="1" rowspan="1">Shortness of breath, fever and generalized weakness</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 136/75</p><p><bold>O2 sat</bold> 99%</p><p><bold>Temp</bold> 36.8C</p><p><bold>HR</bold>&#8201;~&#8201;68</p><p><bold>RR</bold>&#8201;~&#8201;23</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> Atrial flutter with varied AV block</p><p><bold>Chest CT:</bold> no pulmonary embolism</p><p><bold>Echo:</bold> normal LV and RV function and size, mild TR and mild atrial enlargement</p></td><td align="left" colspan="1" rowspan="1">IV dexamethasone and oral anticoagulation</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">29-year-old male</td><td align="left" colspan="1" rowspan="1">Fever, chills, sweats, palpitations, and shortness of breath</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 127/72</p><p><bold>O2 sat</bold> 91%</p><p><bold>Temp</bold> 38.05 C</p><p><bold>HR</bold>&#8201;~&#8201;131</p><p><bold>RR</bold>&#8201;~&#8201;28</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> Irregularly irregular RR interval, no distinct P waves</p><p><bold>Chest CT:</bold> no pulmonary embolism</p><p><bold>Echo:</bold> Mildly dilated LV, severe global LV dysfunction, moderate RV hypokinesis, severe LA enlargement</p></td><td align="left" colspan="1" rowspan="1">IV Cardizem, Metrprolol and flecainide and oral anticoagulation with Eliquis</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">46-year-old black male</td><td align="left" colspan="1" rowspan="1">Fever, cough and shortness of breath</td><td align="left" colspan="1" rowspan="1"><p><bold>SBP</bold> 140</p><p><bold>O2 sat</bold> 88%</p><p><bold>HR</bold>&#8201;~&#8201;142</p><p><bold>RR</bold>&#8201;~&#8201;28</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> Atrial flutter, 2:1 AV block and ST-T changes</p><p><bold>Echo:</bold> preserved LV ejection fraction, no regional wall motion abnormalities</p></td><td align="left" colspan="1" rowspan="1">Amiodarone, digoxin bolus, -blockers, cardioversion 100&#160;J and oral anticoagulation</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">59-year-old male</td><td align="left" colspan="1" rowspan="1">Palpitations, exertional dyspnea and fatigue</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 134/90</p><p><bold>O2 sat</bold> 96%</p><p><bold>Temp</bold> 37.3 C</p><p><bold>HR</bold>&#8201;~&#8201;136</p><p><bold>RR</bold>&#8201;~&#8201;16</p></td><td align="left" colspan="1" rowspan="1"><p><bold>EKG:</bold> Atrial fibrillation with PR 134&#160;bpm and abnormal R wave progression</p><p><bold>Chest CT:</bold> unremarkable</p><p>Echo: moderate LV hypertrophy, LV ejection fraction 60%. Normal LV and LA size</p></td><td align="left" colspan="1" rowspan="1">IV followed by oral Diltiazem and cardioversion</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">56-year-old Hispanic male</td><td align="left" colspan="1" rowspan="1">Malaise and palpitations. Presented to the urgent care previously with fever, chills, night sweats, headaches and palpitations</td><td align="left" colspan="1" rowspan="1"><p><bold>BP</bold> 124/100</p><p><bold>O2 sat</bold> normal</p><p><bold>Temp</bold> 38.8 C</p><p><bold>HR</bold>&#8201;~&#8201;130&#8211;140</p><p><bold>RR</bold>&#8201;~&#8201;16</p></td><td align="left" colspan="1" rowspan="1"><bold>EKG</bold>: Atrial fibrillation with PR 131&#160;bpm along with evidence of LV hypertrophy</td><td align="left" colspan="1" rowspan="1">IV Diltiazem and fluid bolus</td><td align="left" colspan="1" rowspan="1">Restoration of sinus rhythm with clinical recovery</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec9"><title>Clinical management</title><p id="Par78">Atrial fibrillation is regarded as an important risk factor for Major Adverse Cardiovascular events (MACE) such as all point death, heart failure, myocardial infarction and stroke [<xref ref-type="bibr" rid="CR63">63</xref>]. According to a study done by Cutler et al. both previous and current A-fib in COVID-19 patients is associated with worse clinical outcomes [<xref ref-type="bibr" rid="CR63">63</xref>]. Accordingly, efforts should be made to carefully diagnose, monitor and treat A-fib in a prompt manner for preventing adverse consequences in COVID-19 patients. Treatment of new-onset atrial fibrillation in COVID-19 is necessary for restoring the sinus rhythm as well as for optimizing the cardiac output. This can accomplished with therapeutic modalities including rate and rhythm control medications [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Another important aspect of management of atrial fibrillation is preventing the future risk of thromboembolism with the administration of preventive anticoagulant therapy [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Since COVID-19 infections are associated with many complications such as electrolyte disturbances (hypokalemia, hyponatremia, hypomagnesemia and hypocalcemia) and hypoxia that can precipitate AF, efforts should be made to address these abnormalities in addition to offering therapeutic medications [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The presence of hemodynamic stability COVID-19 patients with new-onset A-Fib is one of the most critical determining factor for administration of cardioversion [<xref ref-type="bibr" rid="CR6">6</xref>]. In patients without any cardiovascular instability, it is would be prudent to administers rate controlling medications including Class II agents (&#946;-blockers&#8212;Carvedilol, Metoprolol and Esmolol), Class IV agents (Calcium Channel blocker [CCBs] agents&#8212;Diltiazem and Verapamil) and Digoxin [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. In the contrary, presence of hemodynamic instability with COVID-19 patients with A-Fib warrants delivery of cardioversion along with rhythm control agents including IA (Procainide, Disophyramide and Quinidine), IC (Flecanide and Propafenone) and III class agents (Amiodarone, Dronedarone, Dofetilide, Ibutilide and Sotalol) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Anticoagulation in COVID-19 patients with atrial fibrillation is accomplished by drugs including Direct Xa factor inhibitors (Apixaban, Rivaroxaban and Edoxaban), Direct thrombin inhibitors (Dabigatran), Vitamin-K antagonist (Warfarin) and heparin [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The preferred choice of rate control agents depends on the presence or absence of congestive heart failure (CHF) [<xref ref-type="bibr" rid="CR64">64</xref>]. In the absence of CHF, rate control is achieved via usage of &#946;-blockers, CCBs, digoxin and amiodarone [<xref ref-type="bibr" rid="CR64">64</xref>]. On the other hand, the presence of acute decompensated CHF in critically ill COVID-19 warrants administration of digoxin or amiodarone [<xref ref-type="bibr" rid="CR64">64</xref>]. The choice of rhythm control drugs in COVID-19 patients depends on the presence of absence of structural heart disease [<xref ref-type="bibr" rid="CR64">64</xref>]. In the absence of structural heart disease, Amiodarone, Flecainide, Ibutilide and Sotalol are the drugs of choice for achieving rhythm control [<xref ref-type="bibr" rid="CR64">64</xref>]. In the presence of myocarditis or CHF or coronary artery disease, rhythm control is attained through administration of Amiodarone or Dofetilde or sotalol [<xref ref-type="bibr" rid="CR64">64</xref>]. The role of catheter ablation in COVID-19 patients with A-fib is controversial although it is usually reserved in patients experiencing significant heart failure, frequent emergency department visits and those having significantly higher risk of thromboembolism [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par79">Emergent need of catheter ablation is warranted in A-Fib with severe symptoms and hemodynamic instability or collapse, A-Fib refractory to cardioversion/drugs/rate control, refractory A-Fib with several emergency department visits and A-fib with syncope or cardiac arrest [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. On the contrary, elective catheter ablation is considered in COVID-19 patients with stable heart function, comorbidities and no future risk of hospitalization secondary to A-Fib [<xref ref-type="bibr" rid="CR66">66</xref>]. Comparison of preoperative practices (transesophageal echocardiography) and acute procedural outcomes of catheter ablation during and before COVID-19 pandemic revealed lesser rate of COVID-19 transmission, reduced complication rate and higher same day discharges in the 2020 cohort compared to 2019 cohort. These findings emphasize that complex electrophysiological procedures can be safety administered to high-risk COVID-19 patients with atrial fibrillation results in optimal clinical outcomes while maintaining the quality of care [<xref ref-type="bibr" rid="CR67">67</xref>]. Analysis of 269 patients who underwent catheter ablation for arrhythmia in COVID-19 patients from January 1, 2020, to March 24, 2020, revealed arrhythmia-free survival in 95.9% patients, no COVID-19 infections reported during brief hospitalization period (3&#8211;5&#160;days), and no COVID-19 infections during 3-month follow-up [<xref ref-type="bibr" rid="CR68">68</xref>]. Although physician&#8217;s risk assessment is vital in identifying the COVID-19 patients suitable for catheter ablation, application of quality of life AFEQT questionnaire (Atrial Fibrillation Effect on Quality of Life) was more sensitive in providing insights into their symptom perception, functional impairment and treatment concerns as well in recognizing the high-risk A-fib patients preferable for the procedure during hospital admissions [<xref ref-type="bibr" rid="CR69">69</xref>]. The treatment modalities used for the management of COVID-19-induced A-Fib is summarized in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Treatment options in management of COVID-19 induced A-fib</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="43044_2023_359_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Drug&#8211;drug interactions encountered in management of COVID-19 patients with A-Fib</title><p id="Par80">The medications used to control A-Fib should be used cautiously as they can interact with therapeutic drugs used to neutralize the COVID-19 virus and attenuate the associated systemic inflammation. The interactions can be classified as (a) serious interactions needing to modify the drug regimen, (b) moderate interactions necessitating close monitoring and follow-up, (c) minor interactions that required caution while administering drugs and (d) no interactions where medications can be given with no follow-up. These interactions are summarized in the Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.</p></sec><sec id="Sec11"><title>Thrombosis and systemic thromboembolism in COVID-19-induced A-Fib</title><p id="Par81">The presence of COVID-19 infection along with A-fib substantially increases the thrombogenic risk. The underlying risk factors that increased the risk of thrombogenic risk in COVID-19 patients can range from cytokine storm, microvascular inflammation, increased D-dimer levels, upregulated factor VIII levels, loss of endothelial integrity, platelet activation to deposition of platelets in multiple organs [<xref ref-type="bibr" rid="CR7">7</xref>]. The initial precipitating event that incites thrombogenesis in A-Fib is increased velocity and blood flow through the enlarged left atrium. This will set in motion cascade of events that increases the probability of developing intra-atrial thrombus and subsequent systemic thromboembolism including stroke [<xref ref-type="bibr" rid="CR7">7</xref>]. Rapid speed and flux of blood flow provokes the dislodgement of protective glycocalyx from the vascular endothelium and exposes it to circulating platelets [<xref ref-type="bibr" rid="CR7">7</xref>] (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Platelets tend to accumulate in these bared vascular endothelia by taking the assistance of von Willebrand factor and collagen [<xref ref-type="bibr" rid="CR7">7</xref>]. This platelet accumulation generates thrombin, which will subsequently convert fibrinogen into fibrin leading to thrombus generation and stabilization [<xref ref-type="bibr" rid="CR7">7</xref>] (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Other predisposing factors that are conducive to thrombus formation in atrial fibrillation include stasis, endotheliitis, complement activation, neutrophil extracellular trap formation, hyperviscosity, macrophage activation and thrombotic microangiopathy [<xref ref-type="bibr" rid="CR70">70</xref>] (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Stasis, hyper-coagulable state and vascular inflammation (Virchow&#8217;s Triad) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>) in combination are responsible for occurrence of thrombosis and embolism in COVID-19-induced AF [<xref ref-type="bibr" rid="CR71">71</xref>]. Moderate to severe COVID-19 patients are more likely to be admitted to ICU for longer periods, thereby making them to susceptible to stasis of blood within their vasculature [<xref ref-type="bibr" rid="CR71">71</xref>]. COVID-19 infection was shown to be associated with vasculitis of cutaneous and systemic blood vessels, a predisposing factor for subsequent development of cryptogenic stroke and thromboembolic complications in these patients [<xref ref-type="bibr" rid="CR71">71</xref>]. Hyper-coagulable state that develops in COVID-19-induced A-Fib is attributed to cytokine storm within vascular endothelium of microvasculature within atrial myocardium [<xref ref-type="bibr" rid="CR71">71</xref>]. These pro-inflammatory cytokines can directly stimulate the platelet activation and upregulate the synthesis of tissue factor (TF), Von-willebrand factor and factor VIII [<xref ref-type="bibr" rid="CR71">71</xref>]. This results in increased thrombin generation and subsequent fibrin clot deposition leading to formation of thrombus within atrial chambers [<xref ref-type="bibr" rid="CR71">71</xref>]. Atrial thrombus formation is considered a forewarning for future occurrence of thromboembolism that can manifest as stroke or transient ischemic attacks (TIA) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). The occurrence of atrial fibrillation in COVID-19 patients with risk factors such as diabetes, hypertension and hyperlipidemia leads to inflammation and oxidative stress within the vascular endothelium.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Mechanism of thrombogenesis in COVID-19 induced Afib</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="43044_2023_359_Fig4_HTML.jpg"/></fig></p><p id="Par82">These pathological events drive atherosclerotic plaque formation, remodeling and endothelial damage, which ultimately leads to athero-thrombosis and thromboembolism [<xref ref-type="bibr" rid="CR72">72</xref>]. CHADS2 scores and AF burden are two most important clinical factors that are taken into consideration while assessing the patient risk of thromboembolism [<xref ref-type="bibr" rid="CR73">73</xref>]. The risk of stroke in patients with CHADS2 score 1 and continuous A-Fib, CHADS2 score 2 and no A-Fib burden and CHADS2 score 3 irrespective of A-Fib burden is 5%, 1% and 5% [<xref ref-type="bibr" rid="CR73">73</xref>]. In a recent conducted ASSERT study (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) assessing 2580 patients, the risk of stroke in patients with AF episodes lasting for&#8201;&lt;&#8201;17.7&#160;h and&#8201;&gt;&#8201;17.7&#160;h is 1.3-fold and fivefold, respectively [<xref ref-type="bibr" rid="CR74">74</xref>]. Studies indicate that continuous A-fib episodes lasting up to 48&#160;h are usually sufficient for thrombus formation and subsequent stroke development. These high-risk patients usually benefit from anticoagulant therapy, which reduced the risk of thromboembolism (stroke) drastically by 65% [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par83">Patients having A-Fib greater than 48&#160;h are managed with 3&#160;weeks of anticoagulation and transesophageal echocardiography before they are subjected to cardioversion [<xref ref-type="bibr" rid="CR75">75</xref>]. On the other hand, patients experiencing A-Fib that is acute in onset and less than 48&#160;h can be started on anticoagulation any time before they are considered eligible for cardioversion [<xref ref-type="bibr" rid="CR75">75</xref>]. All A-Fib patients should be considered for long term anticoagulation based on their CHADS2 score, AF burden, bleeding risk and thromboembolism risk [<xref ref-type="bibr" rid="CR75">75</xref>].</p><p id="Par84">The incidence of stroke in patients with COVID-19-induced A-Fib can range from 28 to 33% [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Ischemic stroke is more common than hemorrhagic stroke in patients with COVID-19 patients with small percentage of them presenting with intracranial herniation secondary to hematoma [<xref ref-type="bibr" rid="CR71">71</xref>]. Retrospective analysis of COVID-19 patients revealed that ischemic stroke is the most common neuro-radiological finding (27%) followed by micro-hemorrhages (18%) [<xref ref-type="bibr" rid="CR78">78</xref>]. Another retrospective observational study looking into risk factors, stroke characteristics and clinical outcomes in a large health care system in New York City from March 1, 2020, to April 30, 2020, revealed that atrial fibrillation/flutter, cardioembolic and cryptogenic stroke are present in 10%, 28.9 and 51.8% of COVID-19 patients [<xref ref-type="bibr" rid="CR77">77</xref>]. In a community-based longitudinal study involving 15,000 older black patients, the occurrence of A-fib was associated with twofold increased risk of venous thromboembolism (VTE) and concurrently VTE increased the propensity of developing A-Fib by twofold [<xref ref-type="bibr" rid="CR79">79</xref>]. In a Swedish Nationwide Registry Study, the incidence of VTE was higher in both men and women within first 30&#160;days after A-Fib diagnosis with hazard ratios 6.64 (95% confidence interval, 5.74&#8211;7.69) and 7.56 (95% confidence interval, 6.47&#8211;8.83) and administration of anticoagulation was shown to protective against VTE and stroke [<xref ref-type="bibr" rid="CR80">80</xref>]. VTE in the setting of COVID-19-induced A-fib might also be associated with pulmonary embolism [<xref ref-type="bibr" rid="CR81">81</xref>]. In a recently conducted community study, it is apparent that the risk of developing pulmonary embolism (PE) is very high during first 6&#160;months of A-Fib [<xref ref-type="bibr" rid="CR79">79</xref>]. The mechanism of developing PE in the patients with COVID-19-induced A-Fib is not very clear although some hypothesis were proposed to explain its occurrence.</p><p id="Par85">Formation of thrombus in the left atrium (LA) and left atrial appendage (LAA) can be sometimes associated with thrombus formation in the right atrium (RA) and right atrial appendage (RAA) [<xref ref-type="bibr" rid="CR81">81</xref>]. Echocardiography studies suggest that LA and LAA (10&#8211;15%) are more likely to harbor thrombus compared to RA and RAA (0.4&#8211;7.5%) due to differences in location, anatomy and morphology [<xref ref-type="bibr" rid="CR81">81</xref>&#8211;<xref ref-type="bibr" rid="CR83">83</xref>]. The percentage of patients with thrombus formation in LA and RA unveiled in a previously conducted autopsy study is approximately 12.6% and 7.5%, respectively [<xref ref-type="bibr" rid="CR84">84</xref>]. In the contrary, the approximate risk of thrombus formation in LAA and RAA is around 10.3% and 0.75%, respectively [<xref ref-type="bibr" rid="CR81">81</xref>]. Most of the patients with diagnosed PE are routinely managed with trans-thoracic echocardiography instead of transesophageal echocardiography, which does not have the technical capability to identify a potential RAA thrombus. Thus, RAA thrombus even though it is present in minority set of patients fails to get spotted with current clinical practice guidelines. The formation of RAA thrombus poses a dangerous risk of developing PE because a wide opening of the RAA ostium may increase the odds of migration of RAA thrombus toward the pulmonary vasculature, getting caught in the venous system and eventually blocking the pulmonary outflow.</p><p id="Par86">Pulmonary embolism is more likely to develop in COVID-19 patients with cardiovascular risk factors, and atrial fibrillation is the most common cardiometabolic risk factor encountered in them [<xref ref-type="bibr" rid="CR85">85</xref>]. Activation of thrombogenic pathways globally in systemic tissues can be the underlying mechanism leading to pulmonary embolism in COVID-19-induced A-fib patients [<xref ref-type="bibr" rid="CR7">7</xref>]. Higher incidence of pulmonary embolism in patients with COVID-19 and A-fib can be rationalized by the presence of multiple sub-cellular aberrations such as endothelial dysfunction, inflammation, platelet activation, adrenergic overstimulation and venous stasis confined to right atrial myocardium and venous blood vessels [<xref ref-type="bibr" rid="CR7">7</xref>]. Blood clots formed in RA and venous vasculature as a results of these aberrations can embolize into pulmonary vasculature leading to pulmonary embolism. Earlier studies convey the message that pulmonary embolism was occurring at much rate in the earlier stages of COVID-19 pandemic, and this incidence was substantially reduced by inclusion of potent thromboprophylaxis drugs in COVID-19 management [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par87">A retrospective cohort study conducted uncovered the fact that the presence of A-fib in patients with pulmonary embolism increased the risk of mortality at 1-month and 6-month interval [<xref ref-type="bibr" rid="CR87">87</xref>]. On the contrary, development of pulmonary embolism in COVID-19 patients might increase the chance of developing A-fib via provoking changes including right ventricular strain/dilation, sympathetic overstimulation, myocardial ischemia and wreckage of atrioventricular (AV) node [<xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec12"><title>COVID-19-induced A-fib degenerating into ventricular arrhythmias</title><p id="Par88">COVID-19-induced A-Fib might secondarily precipitate ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) via abbreviated AV node refractory period during exercise, sympathetic overstimulation, ventricular myopathy and genetic variations [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. In a multicenter prospective study where 204 COVID-19 patients were evaluated 3&#160;months after diagnosis, ECG evaluation showed that atrial fibrillation, non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC) in 5%, 18% and 4% cases, respectively [<xref ref-type="bibr" rid="CR91">91</xref>]. COVID-19 patients who develop frequent PVCs (&gt;&#8201;120 per 24&#160;h) should be monitored carefully by assessing pro-BNP (Brain Natriuretic peptide) and hs-cTn (High Sensitivity Cardiac Troponin) which might potentially reveal the occurrence of overt myocardial injury [<xref ref-type="bibr" rid="CR91">91</xref>]. Any consistent elevation of these markers can herald the onset of PVC induced cardiomyopathy manifesting as progressive heart failure characterized by LV dilation and dysfunction in the absence of major cardiac abnormality and complete reversal post successful catheter ablation of PVCs [<xref ref-type="bibr" rid="CR92">92</xref>].</p><p id="Par89">Recently, a patient with protracted COVID-19 infection that presented with chest pain, palpitations and shortness of breath was found to have PVC bigeminy and elimination of these with catheter ablation resulted in successful clinical outcomes [<xref ref-type="bibr" rid="CR93">93</xref>]. In a prospective analysis performed in Shahid Mostafa Khomeini Hospital of Ilam in Iran from March to August, 2020, it was revealed that A-Fib and PVC (20%) are the most common arrhythmias followed by VT (4.44%) and VF (2.22%) [<xref ref-type="bibr" rid="CR94">94</xref>]. In a worldwide retrospective analysis of hospitalized COVID-19 patients, atrial fibrillation, NSVT, VT and VF occurred in 62%, 9.2%, 8.2% and 4% of these cases, respectively [<xref ref-type="bibr" rid="CR95">95</xref>]. In a prospective observational study performed in the hospitalized COVID-19 patients from March 15 to April 30, 2020, subjected to telemetry, the incidence of ventricular arrhythmias include PVC (28.7%), NSVT (15.4%), VT (1.4%) and VF (0.7%), respectively [<xref ref-type="bibr" rid="CR96">96</xref>]. Another interesting finding in this study is that new-onset atrial fibrillation and serious ventricular arrhythmias only occurred in patients with elevated troponin levels [<xref ref-type="bibr" rid="CR96">96</xref>]. Since COVID-19 virus is notorious to inflict myocarditis, concomitant presence of benign (PVC, VT and NSVT) and malignant (VF) ventricular arrhythmias is bound to be expected [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. In a recent case report, a 68-year-old Caucasian women hospitalized for COVID-19 infection developed electrical storm due to sustained and non-sustained VT, which were not controlled by implantable cardioverter defibrillator (ICD) shock therapy [<xref ref-type="bibr" rid="CR98">98</xref>]. Eventually, she underwent substrate-based VT catheter ablation resulting in complete resolution of arrhythmias [<xref ref-type="bibr" rid="CR98">98</xref>]. The authors argue that a combination of factors ranging from myocardial involvement, cytokine storm, hypoxia, intracellular calcium overload to early after-depolarization might be responsible for manifestation of ventricular arrhythmias during the clinical course of COVID-19 patients [<xref ref-type="bibr" rid="CR98">98</xref>].</p></sec><sec id="Sec13"><title>Is there a link between the vaccination and COVID-19-induced A-fib?</title><p id="Par90">New-onset A-fib is most commonly associated with Pfizer followed by Moderna and Johnson and Johnson vaccines [<xref ref-type="bibr" rid="CR99">99</xref>]. According to Vaccine Adverse Reporting System (VAERS), after administration of 532 million doses of vaccine, the number of total and new-onset A-fib cases reported is 2611 and 315, respectively [<xref ref-type="bibr" rid="CR99">99</xref>]. The average incidence of A-fib cases is approximately 5 per 1 million doses vaccine administered [<xref ref-type="bibr" rid="CR99">99</xref>]. Another meta-analysis study indicated that the incidence of A-fib post COVID-19 vaccination is around 1&#8211;76 per 10,000 vaccine doses administered [<xref ref-type="bibr" rid="CR100">100</xref>]. It is being speculated that vaccine administration leads to local and systemic changes including ion channel aberrations, calcium dys-homeostasis and atrial remodeling, thereby priming the myocardial cells for developing A-fib [<xref ref-type="bibr" rid="CR101">101</xref>]. Moreover, it is not possible to rule out the development of autoimmunity and subsequent deposition of immune complexes in atrial myocardium in the pathogenesis of atrial fibrillation post vaccination in the COVID-19 patients. Furthermore, the stress, anxiety and fear associated with vaccination were indirectly linked to the development of A-fib in the COVID-19 patients [<xref ref-type="bibr" rid="CR102">102</xref>]. Mechanistically, these negative emotions tend to destabilize the autonomic nervous system by energizing the sympathetic arm while deactivating the parasympathetic component, thereby kick-starting arrhythmogenic pathways that are pivotal in provoking atrial fibrillation even in patients without structural heart disease [<xref ref-type="bibr" rid="CR102">102</xref>]. On the contrary, vaccination in the hospitalized patients with COVID-19 reduced risk of developing A-fib by 12% (adjusted HR&#8201;=&#8201;0.88, 95%CI 0.79&#8211;0.93) [<xref ref-type="bibr" rid="CR103">103</xref>].</p></sec><sec id="Sec14"><title>Future directions for research</title><p id="Par91">Deposition of fibrous tissue, scar formation and generation of atrial substrate in the atrial myocytes are hypothesized to be some of the most critical driving mechanisms for initiating and sustaining A-Fib. Fundamentally, two main types of fibrosis namely reactive fibrosis and replacement fibrosis can potentially occur in atrial chambers in pathological states [<xref ref-type="bibr" rid="CR104">104</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Reactive fibrosis is process where collagen deposition occurs in the periphery of cardiomyocytes, whereas replacement fibrosis occurs when collagen accumulation tend to replace the dying cardiomyocytes within the myocardium [<xref ref-type="bibr" rid="CR104">104</xref>]. Anatomically, with fibrous tissue interspersing between the myocytes there might be conduction disturbances more commonly associated with replacement fibrosis than reactive fibrosis [<xref ref-type="bibr" rid="CR104">104</xref>]. It has been speculated that pathological disease processes occurring in atrial chambers tend to incite both these types of fibrosis in varying proportions and their relative ratio is very crucial in determining whether they pave the way toward development of atrial arrhythmias [<xref ref-type="bibr" rid="CR104">104</xref>]. Therefore, it would be prudent to investigate the relative percentages of reactive and replacement fibrosis in COVID-19-infected cardiomyocytes in atrial chambers. Identifying the threshold of atrial fibrosis that is necessary for triggering of atrial fibrillation/flutter with COVID-19 infections would be beneficial. This will eventually shed light on the underlying mechanisms that predispose to development of atrial substrate, a key molecular finding that incites atrial fibrillation. Furthermore, it would be worthwhile to characterize the influence of COVID-19-induced atrial fibrosis on atrial myocyte electrophysiological properties such as conduction, ectopic generation, reentry mechanisms, refractory period and action potential duration [<xref ref-type="bibr" rid="CR105">105</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Scope of future research in COVID-19 induced research</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="43044_2023_359_Fig5_HTML.jpg"/></fig></p><p id="Par92">Previous studies suggest that calcium entry in atrial fibroblast is very important for their survival and activation of fibrogenic pathways [<xref ref-type="bibr" rid="CR104">104</xref>]. The main incentive for calcium gaining access into atrial fibroblasts is their resting membrane potential (RMP), which is primarily regulated by inward rectifier potassium current (<italic toggle="yes">I</italic><sub>k1</sub>) [<xref ref-type="bibr" rid="CR106">106</xref>]. Pathological process such as heart failure tends to hyperpolarize the RMP of atrial fibroblasts by activating <italic toggle="yes">I</italic><sub>k1</sub> currents and thus provides a potent stimulus for enhanced calcium entry [<xref ref-type="bibr" rid="CR106">106</xref>]. Extracellular calcium enters into atrial fibroblasts through three important channels, namely store-operated channels (SOC), receptor-operated channels (ROC) and transient receptor potential (TRP) channels, and causes extracellular signal-related kinase (ERK) pathway mediated activation leading to stimulation of fibrogenic pathways as well as fibroblast survival [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Future research studies should be focused on investigating the effects of COVID-19 virus on RMP, calcium channels and ERK pathways in atrial fibroblasts (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). This might provide indirect information regarding the downstream signaling mechanisms that underlie enhanced fibrogenesis and atrial substrate formation in atrial myocardium for development of atrial fibrillation.</p><p id="Par93">In vitro study performed to assess the interactions between fibroblasts isolated from infarcted hearts and neonatal myocytes, there is decreased conduction velocity, attenuated action potential duration, hyperpolarization of RMP, increased gap junction expression and increased intercellular coupling between myocytes and fibroblasts [<xref ref-type="bibr" rid="CR109">109</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Accordingly, enhanced interactions between cardiomyocytes and fibroblasts are shown to enhance ectopic impulse generation and facilitate generation of re-entrant arrhythmias [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. In contrast to these findings, increasing the intercellular interactions between cardiac fibroblasts and cardiomyocytes by increasing the expression of connexin-43 reduced the risk of developing ventricular tachycardia post myocardial infarction [<xref ref-type="bibr" rid="CR112">112</xref>]. Therefore, we can speculate COVID-19-induced myocardial injury might alter intercellular interactions between upregulated fibroblasts and atrial myocytes. Characterizing the downstream effects of these intercellular interactions between them and assessing their end targets would unravel the underlying pathogenic mechanisms for development of atrial arrhythmias in COVID-19-induced myocardium (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par94">Mechanical stretch of cardiomyocytes stimulates the secretion of pro-fibrotic signals such as angiotensin-II, transforming growth factor (TGF)-1&#946;, endothelin-1 (ET-1) and platelet-derived growth factor (PDGF) [<xref ref-type="bibr" rid="CR105">105</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Pro-fibrotic signals act upon neighboring fibroblasts in a paracrine fashion to enhance the synthesis of collagen and other extracellular matrix (ECM) proteins and thus causing atrial fibrosis, and atrial fibrillation [<xref ref-type="bibr" rid="CR105">105</xref>]. Clinical evidence indicating that angiotensin-II is involved in facilitating cardiac fibrosis comes from the fact that losartan (ACE inhibitor) is routinely prescribed in heart failure for suppress cardiac fibrosis in humans [<xref ref-type="bibr" rid="CR113">113</xref>]. Furthermore, ACE inhibitors and AT-1 receptor antagonists were marginally successful in attenuating atrial fibrogenesis and suppressing A-Fib in animal models [<xref ref-type="bibr" rid="CR105">105</xref>]. TGF-1&#946; is hypothesized to act via TGF-1&#946;-activated kinase (TAK-1) for causing cardiac fibroblast induced ECM and collagen production leading to cardiac fibrosis post cardiac injury [<xref ref-type="bibr" rid="CR113">113</xref>]. PDGF is known to act through enhancing cardiac fibroblast proliferation as well as TGF-1&#946; expression, both of which are conducive for progression of cardiac fibrosis post cardiac injury. Efforts made to neutralize the downstream signaling events of PDGF through application of PDGF antibody had yielded successful outcomes in downgrading atrial fibrosis in heart failure model [<xref ref-type="bibr" rid="CR114">114</xref>]. ET-1 is shown to enhance the collagen production by cardiac fibroblasts and functions as a secondary messenger for Angiotensin-II and TGF-1&#946; for mediating cardiac fibrosis [<xref ref-type="bibr" rid="CR113">113</xref>]. Blockade of ET-1 signaling might be beneficial in halting signaling pathways that mediate atrial fibrosis and can be a potential therapeutic strategy for preventing atrial fibrillation. In a single-center observational study of COVID-19 patients from February 10 to March 13, 2020, echocardiographic follow-up revealed that 57.9% of these patients had increased left atrial (LA) size [<xref ref-type="bibr" rid="CR115">115</xref>]. This increase in left atrial size would cause stretch in the atrial myocytes and would eventually make them to secrete pro-fibrotic signals leading to interactions with adjacent fibroblasts. Therefore, it would be prudent to investigate whether these pro-fibrotic signals would be upregulated with COVID-19 infection of atrial myocytes and to investigate the interactions of these pro-fibrotic signals with adjacent fibroblasts.</p><p id="Par95">The relationship between atrial fibrosis and atrial arrhythmogenicity is complex, but few previous studies tried to partially explain it by intracellular calcium overload, oxidative stress, &#945;-SMA (Alpha- Smooth Muscle Actin) over expression and exaggerated myocyte&#8211;fibroblast coupling leading to electrical remodeling, enhanced arrhythmogenesis, ectopic impulse generation and abnormal impulse conduction [<xref ref-type="bibr" rid="CR116">116</xref>&#8211;<xref ref-type="bibr" rid="CR119">119</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). So, studies focused on assessing whether COVID-19 infection of cardiomyocytes generates cellular abnormalities would be beneficial so that appropriate therapeutic interventions can be designed for halting the generation of atrial arrhythmias.</p><p id="Par96">Inflammation and oxidative stress has been documented to a play a significant role in regulating the role of enzymes and tissue factors that regulate the synthesis and degradation of collagen matrix deposition in the myocardial tissues [<xref ref-type="bibr" rid="CR119">119</xref>]. Previous studies indicate that pro-inflammatory cytokines (TNF-alpha and IL-1 beta) modify the expression of tissue inhibitors of matrix metalloproteinases (TIMP) and matrix metalloproteinases (MMPs) in such a way that there is decreased collagen production and increased collagen degradation [<xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>] (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Oxidative stress with production of ROS has been implicated in promoting fibroblast proliferation, activation of intermediate signaling molecules (ERK, P-38 and JNK), and upregulation of nuclear transcription of pro-fibrotic genes. This might result in increased extracellular matrix (ECM) deposition and collagen in myocardial tissues [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Oxidative stress and inflammatory cytokines are implicated in the disruption of MMP regulation in the cardiomyocytes and cardiac fibroblasts, thereby increasing the risk of remodeling and fibrosis in atrial tissues [<xref ref-type="bibr" rid="CR124">124</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>]. For example, IL-1 beta and TNF-alpha are some of the important regulators of MMP-9 transcription and translation, which is previously incriminated in atrial remodeling and fibrosis [<xref ref-type="bibr" rid="CR127">127</xref>]. Analysis of atrial tissues revealed increased MMP-9 mRNA and protein expression and down-regulated expression of TIMP-1 was associated with increased atrial remodeling and increased propensity toward developing A-fib [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. These above findings highlight the importance of MMPs and TIMPs in physiological regulation of ECM deposition and collagen synthesis.</p><p id="Par97">Since COVID-19 infection of atrial cardiomyocytes is associated with cytokine storm [<xref ref-type="bibr" rid="CR6">6</xref>] and oxidative stress [<xref ref-type="bibr" rid="CR119">119</xref>], it is quite possible that there is underlying imbalance in synthesis of MMPs and TIMPs in the atrial tissues, thereby causing atrial remodeling and fibrosis. Therefore, assessing the expression of MMPs and TIMPs in atrial myocytes of patients developing COVID-19-induced A-fib would shed some light by providing valuable information regarding pathogenesis of atrial fibrosis.</p><p id="Par98">ADAMs (<italic toggle="yes">A D</italic>isintegrin <italic toggle="yes">A</italic>nd <italic toggle="yes">M</italic>etalloproteinase) are membrane bound glycoproteins that are expressed in myocardial tissues (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Their main function is to regulate the intercellular and cell&#8211;matrix interactions in the atrial and ventricular myocardium. Their accessory functions can range from proteolysis, adhesion, cleavage and fusion. In physiological conditions, ADAMs bind to integrins for modulating cell motility, adhesion and migration of fibroblasts [<xref ref-type="bibr" rid="CR130">130</xref>]. Alteration of intercellular and cell&#8211;matrix interactions was previously demonstrated in physiological and pathological conditions of heart [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. Analysis of atrial tissues from 30 patients undergoing open heart surgery revealed that there is increased expression of ADAM10 and ADAM15 as well as increased ADAM /integrin ratios in the fibrillating atrial tissues compared to patients with no history of AF [<xref ref-type="bibr" rid="CR133">133</xref>]. These researchers argue that increased ADAM expression induced structural and transport changes might be accountable for atrial dilation seen in atrial fibrillation [<xref ref-type="bibr" rid="CR133">133</xref>]. Specifically, they hypothesize that modification of expression and interactions of ADAM 10 and 15 with integrins &#946;<sub>1</sub> and &#946;<sub>3</sub> might lay the foundations for structural remolding and subsequent dilation in fibrillating atria [<xref ref-type="bibr" rid="CR130">130</xref>]. These findings make us to contemplate that COVID-19 infection of atrial myocytes might induce changes in ADAMs resulting in altered atrial myocyte&#8211;cell matrix interactions leading to atrial dilation and atrial fibrillation. Investigating this hypothesis would enlighten us regarding the influence of ADAMs in pathogenesis of COVID-19-induced A-fib.</p></sec></sec><sec id="Sec15"><title>Conclusions</title><p id="Par99">A-fib usually occurs acutely in COVID-19 patients admitted to ICU, particularly in those with high-risk factors. On the contrary, some patients presented with atrial fibrillation few months later after complete recovery from COVID-19 infections. These long haulers are known to harbor silent COVID-19 infections in the systemic tissues including myocardium. Clinicians need to be vigilant of this arrhythmia as it can be associated with many life-threatening complications. Prompt management and close monitoring are necessary as it has high chances of recurrence. COVID-19-induced pathological derangements in the myocardium and systemic circulation in combination are accountable for instigation and persistence of this cardiac arrhythmia. This review summarizes the pathophysiology of COVID-19-induced A-fib along with its clinical presentation, diagnosis, management and complications. Understanding the interplay of various risk factors both extra-cardiac and intra-cardiac as well as cellular downstream signaling events is very crucial. Since this is a relatively clinical entity, there is a lot of scope in research to understand its pathophysiology. We summarized the various areas where basic science and clinical research studies need to be concentrated in the near future. Execution of these research studies can generate very useful preliminary data that can help us to comprehend necessary downstream signaling events that happen at the cellular level for initiation and perpetuation of atrial fibrillation in COVID-19 patients. Moreover, the molecular targets that are divulged by these research studies can be exploited for crafting novel diagnostic and therapeutic interventions for reducing morbidity and mortality of this fatal cardiac arrhythmia.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec16"><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="43044_2023_359_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p><bold>Additional file 1</bold>. Drug-drug interactions in the management of Atrial fibrillation encountered in COVID-19 patients.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ICU</term><def><p id="Par4">Intensive care unit</p></def></def-item><def-item><term>A-fib</term><def><p id="Par5">Atrial fibrillation</p></def></def-item><def-item><term>MACE</term><def><p id="Par6">Major adverse cardiovascular events</p></def></def-item><def-item><term>ECG</term><def><p id="Par7">Electrocardiogram</p></def></def-item><def-item><term>NSVT</term><def><p id="Par8">Non-sustained ventricular tachycardia</p></def></def-item><def-item><term>ACE2</term><def><p id="Par9">Angiotensin-converting enzyme 2</p></def></def-item><def-item><term>RAC3</term><def><p id="Par10">Ras-related C3 botulinum toxin substrate3</p></def></def-item><def-item><term>STAT3</term><def><p id="Par11">Signal transducer and activator of transcription-3</p></def></def-item><def-item><term>CX40</term><def><p id="Par12">Connexins40</p></def></def-item><def-item><term>RyR</term><def><p id="Par13">Ryanodine receptors</p></def></def-item><def-item><term>SERCA</term><def><p id="Par14">Sarco-endoplasmic reticulum calcium ATPase</p></def></def-item><def-item><term>PLB</term><def><p id="Par15">Phospholamban</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>CaL</sub></term><def><p id="Par16">Inward depolarizing calcium current</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>Na</sub></term><def><p id="Par17">Inward depolarizing sodium current</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>Ks</sub></term><def><p id="Par18">Slow delayed potassium current</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>Kr</sub></term><def><p id="Par19">Delayed rectifier potassium current</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>to</sub></term><def><p id="Par20">Transient outward potassium current</p></def></def-item><def-item><term>Th1&amp;2 lymphocytes</term><def><p id="Par21">Thymic lymphocytes 1&amp;2</p></def></def-item><def-item><term>IL-6</term><def><p id="Par22">Interleukin-1</p></def></def-item><def-item><term>IL-1</term><def><p id="Par23">Interleukin-1</p></def></def-item><def-item><term>CRP</term><def><p id="Par24">C-reactive protein</p></def></def-item><def-item><term>HERG K+ channel</term><def><p id="Par25">Human ether-a-go-go-related gene K+ channel</p></def></def-item><def-item><term>EAD</term><def><p id="Par26">Early after depolarization</p></def></def-item><def-item><term>DAD</term><def><p id="Par27">Delayed after depolarization</p></def></def-item><def-item><term><italic toggle="yes">I</italic><sub>k1</sub></term><def><p id="Par28">Inward rectifier potassium current</p></def></def-item><def-item><term>MV</term><def><p id="Par29">Mechanical ventilation</p></def></def-item><def-item><term>CCBs</term><def><p id="Par30">Calcium channel blockers</p></def></def-item><def-item><term>CHF</term><def><p id="Par31">Congestive Cardiac Failure</p></def></def-item><def-item><term>AFEQT</term><def><p id="Par32">Atrial fibrillation effect on quality of life</p></def></def-item><def-item><term>TF</term><def><p id="Par33">Tissue factor</p></def></def-item><def-item><term>TIA</term><def><p id="Par34">Transient ischemic attack</p></def></def-item><def-item><term>ASSERT study</term><def><p id="Par35">Asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial</p></def></def-item><def-item><term>VTE</term><def><p id="Par36">Venous thromboembolism</p></def></def-item><def-item><term>PE</term><def><p id="Par37">Pulmonary embolism</p></def></def-item><def-item><term>LA</term><def><p id="Par38">Left atrium</p></def></def-item><def-item><term>LAA</term><def><p id="Par39">Left atrial appendage</p></def></def-item><def-item><term>RAA</term><def><p id="Par40">Right atrial appendage</p></def></def-item><def-item><term>AV node</term><def><p id="Par41">Atrioventricular node</p></def></def-item><def-item><term>WPW</term><def><p id="Par42">Wolf Parkinson White Syndrome</p></def></def-item><def-item><term>PVC</term><def><p id="Par43">Premature ventricular contractions</p></def></def-item><def-item><term>VT</term><def><p id="Par44">Ventricular tachycardia</p></def></def-item><def-item><term>VF</term><def><p id="Par45">Ventricular fibrillation</p></def></def-item><def-item><term>ICD</term><def><p id="Par46">Implantable cardioverter defibrillator</p></def></def-item><def-item><term>RMP</term><def><p id="Par47">Resting membrane potential</p></def></def-item><def-item><term>SOC</term><def><p id="Par48">Store-operated calcium channels</p></def></def-item><def-item><term>TRP</term><def><p id="Par49">Transient receptor potential</p></def></def-item><def-item><term>ERK</term><def><p id="Par50">Extracellular signal-related kinase</p></def></def-item><def-item><term>ET-1</term><def><p id="Par51">Endothelin-1</p></def></def-item><def-item><term>PDGF</term><def><p id="Par52">Platelet-derived growth factor</p></def></def-item><def-item><term>ECM</term><def><p id="Par53">Extracellular matrix</p></def></def-item><def-item><term>TGF-1&#946;</term><def><p id="Par54">Transforming growth factor-1 beta</p></def></def-item><def-item><term>TAK1</term><def><p id="Par55">TGF-1&#946;-activated kinase</p></def></def-item><def-item><term>SMA</term><def><p id="Par56">Smooth muscle actin</p></def></def-item><def-item><term>TIMP</term><def><p id="Par57">Tissue inhibitors of matrix metalloproteinases</p></def></def-item><def-item><term>MMP</term><def><p id="Par58">Matrix metalloproteinases</p></def></def-item><def-item><term>JNK</term><def><p id="Par59">C-Jun N-terminal kinase</p></def></def-item><def-item><term>ADAMs</term><def><p id="Par60"><italic toggle="yes">A D</italic>Isintegrin <italic toggle="yes">A</italic>nd <italic toggle="yes">M</italic>etalloproteinase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>SHK contributed to conception, design, drafting manuscript, figure and table design, editing and final approval. PJS contributed to figure and table preparation, review, editing and final approval. ASU contributed to review, editing and final approval. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No data are presented and analyzed in this manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par100">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par101">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par102">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mountantonakis</surname><given-names>SE</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>M</given-names></name><name name-style="western"><surname>Fishbein</surname><given-names>J</given-names></name><etal/></person-group><article-title>Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection</article-title><source>Heart Rhythm</source><year>2021</year><volume>18</volume><issue>4</issue><fpage>501</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2021.01.018</pub-id><pub-id pub-id-type="pmid">33493650</pub-id><pub-id pub-id-type="pmcid">PMC7825902</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wollborn</surname><given-names>J</given-names></name><name name-style="western"><surname>Karamnov</surname><given-names>S</given-names></name><name name-style="western"><surname>Fields</surname><given-names>KG</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>T</given-names></name><name name-style="western"><surname>Muehlschlegel</surname><given-names>JD</given-names></name></person-group><article-title>COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>12014</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-16113-6</pub-id><pub-id pub-id-type="pmid">35835807</pub-id><pub-id pub-id-type="pmcid">PMC9281233</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblatt</surname><given-names>AG</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>CR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A</given-names></name><etal/></person-group><article-title>New-onset atrial fibrillation in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Registry</article-title><source>Circ Arrhythmia Electrophysiol</source><year>2022</year><volume>15</volume><issue>5</issue><fpage>e010666</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.121.010666</pub-id><pub-id pub-id-type="pmid">35475654</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uribarri</surname><given-names>A</given-names></name><name name-style="western"><surname>N&#250;&#241;ez-Gil</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Aparisi</surname><given-names>&#193;</given-names></name><etal/></person-group><article-title>Atrial fibrillation in patients with COVID-19. Usefulness of the CHA(2)DS(2)-VASc score: an analysis of the international HOPE COVID-19 registry</article-title><source>Rev Esp Cardiol (Engl Ed)</source><year>2021</year><volume>74</volume><issue>7</issue><fpage>608</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.recesp.2020.12.014</pub-id><pub-id pub-id-type="pmid">33583755</pub-id><pub-id pub-id-type="pmcid">PMC7836821</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>J</given-names></name></person-group><article-title>The COVID heart&#8212;one year after SARS-CoV-2 infection, patients have an array of increased cardiovascular risks</article-title><source>JAMA</source><year>2022</year><volume>327</volume><issue>12</issue><fpage>1113</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.2411</pub-id><pub-id pub-id-type="pmid">35234824</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gawa&#322;ko</surname><given-names>M</given-names></name><name name-style="western"><surname>Kap&#322;on-Cie&#347;licka</surname><given-names>A</given-names></name><name name-style="western"><surname>Hohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Dobrev</surname><given-names>D</given-names></name><name name-style="western"><surname>Linz</surname><given-names>D</given-names></name></person-group><article-title>COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications</article-title><source>Int J Cardiol Heart Vasc</source><year>2020</year><volume>30</volume><fpage>100631</fpage><pub-id pub-id-type="pmid">32904969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcha.2020.100631</pub-id><pub-id pub-id-type="pmcid">PMC7462635</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raatikainen</surname><given-names>P</given-names></name><name name-style="western"><surname>Lassila</surname><given-names>R</given-names></name></person-group><article-title>COVID-19: another reason for anticoagulation in patients with atrial fibrillation</article-title><source>Heart</source><year>2022</year><volume>108</volume><issue>12</issue><fpage>902</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2022-320845</pub-id><pub-id pub-id-type="pmid">35314451</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuniadi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yugo</surname><given-names>D</given-names></name><name name-style="western"><surname>Fajri</surname><given-names>M</given-names></name><etal/></person-group><article-title>ECG characteristics of COVID-19 patient with arrhythmias: referral hospitals data from Indonesia</article-title><source>J Arrhythmia</source><year>2022</year><volume>38</volume><issue>3</issue><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1002/joa3.12718</pub-id><pub-id pub-id-type="pmcid">PMC9237289</pub-id><pub-id pub-id-type="pmid">35785388</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Namazi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cardiac arrhythmias in hospitalized patients with COVID-19: a prospective observational study in the western United States</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><issue>12</issue><fpage>e0244533</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244533</pub-id><pub-id pub-id-type="pmid">33370347</pub-id><pub-id pub-id-type="pmcid">PMC7769280</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatla</surname><given-names>A</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>MM</given-names></name><name name-style="western"><surname>Adusumalli</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19 and cardiac arrhythmias</article-title><source>Heart Rhythm</source><year>2020</year><volume>17</volume><issue>9</issue><fpage>1439</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2020.06.016</pub-id><pub-id pub-id-type="pmid">32585191</pub-id><pub-id pub-id-type="pmcid">PMC7307518</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inciardi</surname><given-names>RM</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lupi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>19</issue><fpage>1821</fpage><lpage>1829</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa388</pub-id><pub-id pub-id-type="pmid">32383763</pub-id><pub-id pub-id-type="pmcid">PMC7239204</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence of atrial fibrillation and associated mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>720129</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.720129</pub-id><pub-id pub-id-type="pmid">34722658</pub-id><pub-id pub-id-type="pmcid">PMC8548384</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musikantow</surname><given-names>DR</given-names></name><name name-style="western"><surname>Turagam</surname><given-names>MK</given-names></name><name name-style="western"><surname>Sartori</surname><given-names>S</given-names></name><etal/></person-group><article-title>Atrial fibrillation in patients hospitalized with COVID-19</article-title><source>JACC Clin Electrophysiol</source><year>2021</year><volume>7</volume><issue>9</issue><fpage>1120</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.jacep.2021.02.009</pub-id><pub-id pub-id-type="pmid">33895107</pub-id><pub-id pub-id-type="pmcid">PMC7904279</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fumagalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Trevisan</surname><given-names>C</given-names></name><name name-style="western"><surname>Del Signore</surname><given-names>S</given-names></name><etal/></person-group><article-title>Atrial fibrillation and COVID-19 in older patients: how disability contributes to shape the risk profile. An analysis of the GeroCovid registry</article-title><source>Aging Clin Exp Res</source><year>2022</year><volume>34</volume><issue>1</issue><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1007/s40520-021-02008-5</pub-id><pub-id pub-id-type="pmid">34716570</pub-id><pub-id pub-id-type="pmcid">PMC8556143</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>HM</given-names></name><name name-style="western"><surname>Paciotti</surname><given-names>B</given-names></name><name name-style="western"><surname>Srivatsa</surname><given-names>UN</given-names></name></person-group><article-title>Incidence and implications of atrial fibrillation in patients hospitalized for COVID compared to non-COVID pneumonia: a multicenter cohort study</article-title><source>Heart Rhythm O2</source><year>2023</year><volume>4</volume><issue>1</issue><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.hroo.2022.10.012</pub-id><pub-id pub-id-type="pmid">36439283</pub-id><pub-id pub-id-type="pmcid">PMC9675418</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulrahman</surname><given-names>A</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>T</given-names></name><name name-style="western"><surname>Nawaz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Is atrial fibrillation a risk factor for worse outcomes in severe COVID-19 patients: a single center retrospective cohort</article-title><source>J Saudi Heart Assoc</source><year>2021</year><volume>33</volume><issue>2</issue><fpage>160</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.37616/2212-5043.1255</pub-id><pub-id pub-id-type="pmid">34285872</pub-id><pub-id pub-id-type="pmcid">PMC8274695</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siripanthong</surname><given-names>B</given-names></name><name name-style="western"><surname>Nazarian</surname><given-names>S</given-names></name><name name-style="western"><surname>Muser</surname><given-names>D</given-names></name><etal/></person-group><article-title>Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management</article-title><source>Heart Rhythm</source><year>2020</year><volume>17</volume><fpage>1463</fpage><lpage>1471</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2020.05.001</pub-id><pub-id pub-id-type="pmid">32387246</pub-id><pub-id pub-id-type="pmcid">PMC7199677</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voleti</surname><given-names>N</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>SP</given-names></name><name name-style="western"><surname>Ssentongo</surname><given-names>P</given-names></name></person-group><article-title>Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>9</volume><fpage>951314</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2022.951314</pub-id><pub-id pub-id-type="pmid">36105535</pub-id><pub-id pub-id-type="pmcid">PMC9467278</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadi</surname><given-names>HA</given-names></name><name name-style="western"><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mahmeed</surname><given-names>WA</given-names></name><name name-style="western"><surname>Suwaidi</surname><given-names>JA</given-names></name></person-group><article-title>Inflammatory cytokines and atrial fibrillation: current and prospective views</article-title><source>J Inflamm Res</source><year>2010</year><volume>3</volume><fpage>75</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2147/JIR.S10095</pub-id><pub-id pub-id-type="pmid">22096359</pub-id><pub-id pub-id-type="pmcid">PMC3218735</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mir&#243;</surname><given-names>&#210;</given-names></name><name name-style="western"><surname>Jim&#233;nez</surname><given-names>S</given-names></name><name name-style="western"><surname>Mebazaa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>33</issue><fpage>3127</fpage><lpage>3142</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab314</pub-id><pub-id pub-id-type="pmid">34164664</pub-id><pub-id pub-id-type="pmcid">PMC8344714</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pagnesi</surname><given-names>M</given-names></name><name name-style="western"><surname>Baldetti</surname><given-names>L</given-names></name><name name-style="western"><surname>Beneduce</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19</article-title><source>Heart</source><year>2020</year><volume>106</volume><issue>17</issue><fpage>1324</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2020-317355</pub-id><pub-id pub-id-type="pmid">32675217</pub-id><pub-id pub-id-type="pmcid">PMC7476272</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name></person-group><article-title>Effects of COVID-19 on arrhythmia</article-title><source>J Cardiovasc Dev Dis</source><year>2022</year><volume>9</volume><fpage>292</fpage><pub-id pub-id-type="doi">10.3390/jcdd9090292</pub-id><pub-id pub-id-type="pmid">36135437</pub-id><pub-id pub-id-type="pmcid">PMC9504579</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzerini</surname><given-names>PE</given-names></name><name name-style="western"><surname>Laghi-Pasini</surname><given-names>F</given-names></name><name name-style="western"><surname>Boutjdir</surname><given-names>M</given-names></name><name name-style="western"><surname>Capecchi</surname><given-names>PL</given-names></name></person-group><article-title>Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19</article-title><source>Nat Rev Immunol</source><year>2022</year><volume>22</volume><issue>5</issue><fpage>270</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00714-3</pub-id><pub-id pub-id-type="pmid">35347295</pub-id><pub-id pub-id-type="pmcid">PMC8959266</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavelle</surname><given-names>MP</given-names></name><name name-style="western"><surname>Desai</surname><given-names>AD</given-names></name><name name-style="western"><surname>Wan</surname><given-names>EY</given-names></name></person-group><article-title>Arrhythmias in the COVID-19 patient</article-title><source>Heart Rhythm O2</source><year>2022</year><volume>3</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.hroo.2022.01.002</pub-id><pub-id pub-id-type="pmid">35043098</pub-id><pub-id pub-id-type="pmcid">PMC8758199</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>I</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>N</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19 and anticoagulation for atrial fibrillation: an analysis of us nationwide pharmacy claims data</article-title><source>J Am Heart Assoc</source><year>2021</year><volume>10</volume><issue>24</issue><fpage>e023235</fpage><pub-id pub-id-type="doi">10.1161/JAHA.121.023235</pub-id><pub-id pub-id-type="pmid">34913359</pub-id><pub-id pub-id-type="pmcid">PMC9075244</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poh</surname><given-names>KC</given-names></name><name name-style="western"><surname>Tay</surname><given-names>VYJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>SHX</given-names></name><name name-style="western"><surname>Chee</surname><given-names>H</given-names></name><name name-style="western"><surname>Suhitharan</surname><given-names>T</given-names></name></person-group><article-title>A review of COVID-19-related thrombosis and anticoagulation strategies specific to the Asian population</article-title><source>Singap Med J</source><year>2020</year><volume>63</volume><fpage>350</fpage><lpage>361</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.11622/smedj.2020174</pub-id><pub-id pub-id-type="pmcid">PMC9578119</pub-id><pub-id pub-id-type="pmid">33264831</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafaqat</surname><given-names>S</given-names></name><name name-style="western"><surname>Rafaqat</surname><given-names>S</given-names></name><name name-style="western"><surname>Khurshid</surname><given-names>H</given-names></name><name name-style="western"><surname>Rafaqat</surname><given-names>S</given-names></name></person-group><article-title>Electrolyte&#8217;s imbalance role in atrial fibrillation: pharmacological management</article-title><source>Int J Arrhythmia</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s42444-022-00065-z</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y-Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-C</given-names></name><etal/></person-group><article-title>Electrolyte disturbances differentially regulate sinoatrial node and pulmonary vein electrical activity: a contribution to hypokalemia- or hyponatremia-induced atrial fibrillation</article-title><source>Heart Rhythm</source><year>2016</year><volume>13</volume><issue>3</issue><fpage>781</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2015.12.005</pub-id><pub-id pub-id-type="pmid">26654920</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platonov</surname><given-names>PG</given-names></name><name name-style="western"><surname>McNitt</surname><given-names>S</given-names></name><name name-style="western"><surname>Polonsky</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosero</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>W</given-names></name></person-group><article-title>Atrial fibrillation in long QT syndrome by genotype</article-title><source>Circ Arrhythmia Electrophysiol</source><year>2019</year><volume>12</volume><issue>10</issue><fpage>e007213</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.119.007213</pub-id><pub-id pub-id-type="pmcid">PMC6814383</pub-id><pub-id pub-id-type="pmid">31610692</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandyam</surname><given-names>MC</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>EZ</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group><article-title>The QT interval and risk of incident atrial fibrillation</article-title><source>Heart Rhythm</source><year>2013</year><volume>10</volume><issue>10</issue><fpage>1562</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2013.07.023</pub-id><pub-id pub-id-type="pmid">23872693</pub-id><pub-id pub-id-type="pmcid">PMC3787974</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazzerini</surname><given-names>PE</given-names></name><name name-style="western"><surname>Boutjdir</surname><given-names>M</given-names></name><name name-style="western"><surname>Capecchi</surname><given-names>PL</given-names></name></person-group><article-title>COVID-19, arrhythmic risk, and inflammation</article-title><source>Circulation</source><year>2020</year><volume>142</volume><issue>1</issue><fpage>7</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047293</pub-id><pub-id pub-id-type="pmid">32286863</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name><name name-style="western"><surname>Chun</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>I</given-names></name><etal/></person-group><article-title>Clinical and genetic relationships between the QTc interval and risk of a stroke among atrial fibrillation patients undergoing catheter ablation</article-title><source>Int J Arrhythmia</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s42444-020-00017-5</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P-S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LS</given-names></name><name name-style="western"><surname>Fishbein</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S-F</given-names></name><name name-style="western"><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Role of the autonomic nervous system in atrial fibrillation</article-title><source>Circ Res</source><year>2014</year><volume>114</volume><issue>9</issue><fpage>1500</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303772</pub-id><pub-id pub-id-type="pmid">24763467</pub-id><pub-id pub-id-type="pmcid">PMC4043633</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>SC</given-names></name></person-group><article-title>Evidence for inflammation as a driver of atrial fibrillation</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>7</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.00062</pub-id><pub-id pub-id-type="pmid">32411723</pub-id><pub-id pub-id-type="pmcid">PMC7201086</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichiki</surname><given-names>H</given-names></name><name name-style="western"><surname>Orihara</surname><given-names>K</given-names></name><name name-style="western"><surname>Hamasaki</surname><given-names>S</given-names></name><etal/></person-group><article-title>The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes</article-title><source>J Cardiol</source><year>2009</year><volume>53</volume><issue>1</issue><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2008.09.008</pub-id><pub-id pub-id-type="pmid">19167648</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>T-Y</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T-F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C-J</given-names></name><etal/></person-group><article-title>The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case-control study</article-title><source>Heart Rhythm</source><year>2016</year><volume>13</volume><issue>6</issue><fpage>1189</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2016.01.026</pub-id><pub-id pub-id-type="pmid">26850784</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolton</surname><given-names>A</given-names></name><name name-style="western"><surname>Thyagaturu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>M</given-names></name><name name-style="western"><surname>Carnahan</surname><given-names>R</given-names></name><name name-style="western"><surname>Hodgson-Zingman</surname><given-names>D</given-names></name></person-group><article-title>Effects of atrial fibrillation on outcomes of influenza hospitalization</article-title><source>Int J Cardiol Heart Vasc</source><year>2022</year><volume>42</volume><fpage>101106</fpage><pub-id pub-id-type="pmid">36032267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcha.2022.101106</pub-id><pub-id pub-id-type="pmcid">PMC9403342</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Platt</surname><given-names>MP</given-names></name><name name-style="western"><surname>Gilley</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Influenza causes MLKL-driven cardiac proteome remodeling during convalescence</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><issue>5</issue><fpage>570</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.318511</pub-id><pub-id pub-id-type="pmid">33501852</pub-id><pub-id pub-id-type="pmcid">PMC8313652</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maisano</surname><given-names>A</given-names></name><name name-style="western"><surname>Vitolo</surname><given-names>M</given-names></name><name name-style="western"><surname>Imberti</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Atrial fibrillation in the setting of acute pneumonia: not a secondary arrhythmia</article-title><source>RCM</source><year>2022</year><volume>23</volume><issue>5</issue><fpage>176</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.31083/j.rcm2305176</pub-id><pub-id pub-id-type="pmcid">PMC11273968</pub-id><pub-id pub-id-type="pmid">39077611</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarabi</surname><given-names>G</given-names></name><name name-style="western"><surname>Schnabel</surname><given-names>RB</given-names></name><name name-style="western"><surname>Heydecke</surname><given-names>G</given-names></name><name name-style="western"><surname>Seedorf</surname><given-names>U</given-names></name></person-group><article-title>Potential impact of oral inflammations on cardiac functions and atrial fibrillation</article-title><source>Biomolecules</source><year>2018</year><volume>8</volume><issue>3</issue><fpage>66</fpage><pub-id pub-id-type="doi">10.3390/biom8030066</pub-id><pub-id pub-id-type="pmid">30071583</pub-id><pub-id pub-id-type="pmcid">PMC6164509</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baba</surname><given-names>A</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy</article-title><source>Eur Heart J</source><year>2004</year><volume>25</volume><issue>13</issue><fpage>1108</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.ehj.2004.05.012</pub-id><pub-id pub-id-type="pmid">15231368</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stavrakis</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><issue>14</issue><fpage>1309</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.07.015</pub-id><pub-id pub-id-type="pmid">19778674</pub-id><pub-id pub-id-type="pmcid">PMC2801559</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>K</given-names></name><name name-style="western"><surname>Jahangiri</surname><given-names>M</given-names></name><name name-style="western"><surname>Mukhin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of anti-heat shock protein 65 antibodies with development of postoperative atrial fibrillation</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>17</issue><fpage>2588</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000136825.96029.A5</pub-id><pub-id pub-id-type="pmid">15249499</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagrov</surname><given-names>AY</given-names></name><name name-style="western"><surname>Fedorova</surname><given-names>OV</given-names></name><name name-style="western"><surname>Roukoyatkina</surname><given-names>NI</given-names></name><name name-style="western"><surname>Zhabko</surname><given-names>EP</given-names></name></person-group><article-title>Effect of endogenous digoxin-like factor and digoxin antibody on myocardial Na+, K+-pump activity and ventricular arrhythmias in acute myocardial ischaemia in rats</article-title><source>Cardiovasc Res</source><year>1993</year><volume>27</volume><issue>6</issue><fpage>1045</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1093/cvr/27.6.1045</pub-id><pub-id pub-id-type="pmid">8221762</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maixent</surname><given-names>JM</given-names></name><name name-style="western"><surname>Paganelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Scaglione</surname><given-names>J</given-names></name><name name-style="western"><surname>Levy</surname><given-names>S</given-names></name></person-group><article-title>Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation</article-title><source>J Cardiovasc Electrophysiol</source><year>1998</year><volume>9</volume><issue>6</issue><fpage>612</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8167.1998.tb00942.x</pub-id><pub-id pub-id-type="pmid">9654226</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>KT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Shen</surname><given-names>WK</given-names></name></person-group><article-title>Autoantibodies and cardiac arrhythmias</article-title><source>Heart Rhythm</source><year>2011</year><volume>8</volume><issue>11</issue><fpage>1788</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2011.06.032</pub-id><pub-id pub-id-type="pmid">21740882</pub-id><pub-id pub-id-type="pmcid">PMC3855646</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melduni</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>LT</given-names></name><name name-style="western"><surname>Gersh</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Association of autoimmune vasculitis and incident atrial fibrillation: a population-based case-control study</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>18</issue><fpage>e015977</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.015977</pub-id><pub-id pub-id-type="pmid">32893708</pub-id><pub-id pub-id-type="pmcid">PMC7727002</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>M</given-names></name></person-group><article-title>Autoantibodies in atrial fibrillation: actors, biomarkers or bystanders? How far have we come?</article-title><source>Cardiology</source><year>2009</year><volume>112</volume><issue>3</issue><fpage>178</fpage><pub-id pub-id-type="doi">10.1159/000149151</pub-id><pub-id pub-id-type="pmid">18667820</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouskas</surname><given-names>I</given-names></name><name name-style="western"><surname>Holeva</surname><given-names>V</given-names></name><name name-style="western"><surname>Parlapani</surname><given-names>E</given-names></name><etal/></person-group><article-title>A COVID-19 patient presenting with paroxysmal atrial fibrillation</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>8</issue><fpage>17569</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.17569</pub-id><pub-id pub-id-type="pmcid">PMC8480445</pub-id><pub-id pub-id-type="pmid">34646625</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Umar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ilyas</surname><given-names>U</given-names></name><etal/></person-group><article-title>New-onset atrial fibrillation in COVID-19 infection: a case report and review of literature</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>4</issue><fpage>e23912</fpage><pub-id pub-id-type="pmid">35530910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.23912</pub-id><pub-id pub-id-type="pmcid">PMC9076057</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouchlarhem</surname><given-names>A</given-names></name><name name-style="western"><surname>Haddar</surname><given-names>L</given-names></name><name name-style="western"><surname>Nasri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Brainstem stroke: a fatal thromboembolic event after new onset atrial fibrillation during covid-19 infection: a case report and literature review</article-title><source>Radiol Case Rep</source><year>2021</year><volume>16</volume><issue>11</issue><fpage>3244</fpage><lpage>3249</lpage><pub-id pub-id-type="doi">10.1016/j.radcr.2021.07.090</pub-id><pub-id pub-id-type="pmid">34377221</pub-id><pub-id pub-id-type="pmcid">PMC8343382</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harhay</surname><given-names>J</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah</surname><given-names>S</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>A</given-names></name></person-group><article-title>SARS-COV-2 PRESENTING AS NEW ONSET ATRIAL FIBRILLATION: A Case Report</article-title><source>Cureus</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>e8054</fpage><pub-id pub-id-type="pmid">32537272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.8054</pub-id><pub-id pub-id-type="pmcid">PMC7286580</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Abbas</surname><given-names>O</given-names></name><name name-style="western"><surname>Alshaikhli</surname><given-names>A</given-names></name><name name-style="western"><surname>Amran</surname><given-names>HA</given-names></name></person-group><article-title>New-onset atrial fibrillation and multiple systemic emboli in a COVID-19 patient</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>1</issue><fpage>e12917</fpage><pub-id pub-id-type="pmid">33654600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.12917</pub-id><pub-id pub-id-type="pmcid">PMC7906080</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mann</surname><given-names>H</given-names></name><name name-style="western"><surname>Chaudry</surname><given-names>A</given-names></name><name name-style="western"><surname>Dolkar</surname><given-names>T</given-names></name><name name-style="western"><surname>Dufresne</surname><given-names>A</given-names></name></person-group><article-title>Coronavirus disease 2019 associated acute myocardial infarction and atrial fibrillation: a case report</article-title><source>Cureus</source><year>2022</year><volume>14</volume><issue>11</issue><fpage>e31216</fpage><pub-id pub-id-type="pmid">36505116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.31216</pub-id><pub-id pub-id-type="pmcid">PMC9729071</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Madhavan</surname><given-names>MV</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Extrapulmonary manifestations of COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1017</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0968-3</pub-id><pub-id pub-id-type="pmid">32651579</pub-id><pub-id pub-id-type="pmcid">PMC11972613</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouskas</surname><given-names>I</given-names></name><name name-style="western"><surname>Holeva</surname><given-names>V</given-names></name><name name-style="western"><surname>Parlapani</surname><given-names>E</given-names></name><name name-style="western"><surname>Nikopoulou</surname><given-names>VA</given-names></name><name name-style="western"><surname>Diakogiannis</surname><given-names>I</given-names></name></person-group><article-title>A COVID-19 patient presenting with paroxysmal atrial fibrillation</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>8</issue><fpage>e17569</fpage><pub-id pub-id-type="pmid">34646625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.17569</pub-id><pub-id pub-id-type="pmcid">PMC8480445</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnaubelt</surname><given-names>S</given-names></name><name name-style="western"><surname>Breyer</surname><given-names>MK</given-names></name><name name-style="western"><surname>Siller-Matula</surname><given-names>J</given-names></name><name name-style="western"><surname>Domanovits</surname><given-names>H</given-names></name></person-group><article-title>Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report</article-title><source>Eur Heart J Case Rep</source><year>2020</year><volume>4</volume><issue>Fi1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytaa166</pub-id><pub-id pub-id-type="pmid">33089045</pub-id><pub-id pub-id-type="pmcid">PMC7337643</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santi</surname><given-names>AD</given-names></name><name name-style="western"><surname>Aquino</surname><given-names>P</given-names></name><name name-style="western"><surname>Dorfman</surname><given-names>M</given-names></name></person-group><article-title>Atrial fibrillation in a child with COVID-19 infection</article-title><source>Cardiol Young</source><year>2021</year><volume>31</volume><issue>2</issue><fpage>318</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1017/S1047951120003893</pub-id><pub-id pub-id-type="pmid">33070790</pub-id><pub-id pub-id-type="pmcid">PMC7642508</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohli</surname><given-names>U</given-names></name><name name-style="western"><surname>Meinert</surname><given-names>E</given-names></name><name name-style="western"><surname>Chong</surname><given-names>G</given-names></name><name name-style="western"><surname>Tesher</surname><given-names>M</given-names></name><name name-style="western"><surname>Jani</surname><given-names>P</given-names></name></person-group><article-title>Fulminant myocarditis and atrial fibrillation in child with acute COVID-19</article-title><source>J Electrocardiol</source><year>2022</year><volume>73</volume><fpage>150</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jelectrocard.2020.10.004</pub-id><pub-id pub-id-type="pmid">33268052</pub-id><pub-id pub-id-type="pmcid">PMC7568943</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajouli</surname><given-names>S</given-names></name></person-group><article-title>A 29-year-old man with COVID-19 pneumonia, heart failure-reduced ejection fraction, and atrial fibrillation with a father and 2 grandparents who were positive for SARS-CoV-2 infection</article-title><source>Am J Case Rep</source><year>2021</year><volume>22</volume><fpage>e933163</fpage><pub-id pub-id-type="doi">10.12659/AJCR.933163</pub-id><pub-id pub-id-type="pmid">34294675</pub-id><pub-id pub-id-type="pmcid">PMC8317665</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seecheran</surname><given-names>R</given-names></name><name name-style="western"><surname>Narayansingh</surname><given-names>R</given-names></name><name name-style="western"><surname>Giddings</surname><given-names>S</given-names></name><etal/></person-group><article-title>Atrial arrhythmias in a patient presenting with coronavirus disease-2019 (COVID-19) infection</article-title><source>J Investig Med High Impact Case Rep</source><year>2020</year><volume>8</volume><fpage>2324709620925571</fpage><pub-id pub-id-type="pmid">32370558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2324709620925571</pub-id><pub-id pub-id-type="pmcid">PMC7218462</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taha</surname><given-names>ME</given-names></name><name name-style="western"><surname>Alsafi</surname><given-names>W</given-names></name><name name-style="western"><surname>Taha</surname><given-names>M</given-names></name><name name-style="western"><surname>Eljack</surname><given-names>A</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>H</given-names></name></person-group><article-title>Coronavirus disease and new-onset atrial fibrillation: two cases</article-title><source>Cureus</source><year>2020</year><volume>12</volume><issue>5</issue><fpage>e8066</fpage><pub-id pub-id-type="pmid">32542123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.8066</pub-id><pub-id pub-id-type="pmcid">PMC7290110</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>MJ</given-names></name><name name-style="western"><surname>May</surname><given-names>HT</given-names></name><name name-style="western"><surname>Bair</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19</article-title><source>IJC Heart Vasc</source><year>2022</year><volume>43</volume><fpage>101127</fpage><pub-id pub-id-type="doi">10.1016/j.ijcha.2022.101127</pub-id><pub-id pub-id-type="pmcid">PMC9513337</pub-id><pub-id pub-id-type="pmid">36188756</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rattanawong</surname><given-names>P</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W</given-names></name><name name-style="western"><surname>Masry</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Guidance on short-term management of atrial fibrillation in coronavirus disease 2019</article-title><source>J Am Heart Assoc</source><year>2020</year><volume>9</volume><issue>14</issue><fpage>e017529</fpage><pub-id pub-id-type="doi">10.1161/JAHA.120.017529</pub-id><pub-id pub-id-type="pmid">32515253</pub-id><pub-id pub-id-type="pmcid">PMC7660727</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y-F</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W-H</given-names></name><name name-style="western"><surname>Hung</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Management of atrial fibrillation in COVID-19 pandemic</article-title><source>Circ J</source><year>2020</year><volume>84</volume><issue>10</issue><fpage>1679</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-20-0566</pub-id><pub-id pub-id-type="pmid">32908073</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakkireddy</surname><given-names>DR</given-names></name><name name-style="western"><surname>Chung</surname><given-names>MK</given-names></name><name name-style="western"><surname>Gopinathannair</surname><given-names>R</given-names></name><etal/></person-group><article-title>Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association</article-title><source>Circulation</source><year>2020</year><volume>141</volume><issue>21</issue><fpage>e823</fpage><lpage>e831</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047063</pub-id><pub-id pub-id-type="pmid">32228309</pub-id><pub-id pub-id-type="pmcid">PMC7243667</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbhaiya</surname><given-names>CR</given-names></name><name name-style="western"><surname>Wadhwani</surname><given-names>L</given-names></name><name name-style="western"><surname>Manmadhan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rebooting atrial fibrillation ablation in the COVID-19 pandemic</article-title><source>J Interv Card Electrophysiol</source><year>2022</year><volume>63</volume><issue>1</issue><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s10840-021-00952-w</pub-id><pub-id pub-id-type="pmid">33543350</pub-id><pub-id pub-id-type="pmcid">PMC7861463</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Management of catheter ablation in arrhythmia patients during the coronavirus disease 2019 epidemic</article-title><source>ESC Heart Fail</source><year>2020</year><volume>7</volume><issue>6</issue><fpage>4032</fpage><lpage>4039</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13009</pub-id><pub-id pub-id-type="pmid">32940415</pub-id><pub-id pub-id-type="pmcid">PMC7754755</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pius</surname><given-names>C</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>H</given-names></name><name name-style="western"><surname>Snowdon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Impact of COVID-19 on patients awaiting ablation for atrial fibrillation</article-title><source>Open Heart</source><year>2022</year><volume>9</volume><issue>1</issue><fpage>e001969</fpage><pub-id pub-id-type="doi">10.1136/openhrt-2022-001969</pub-id><pub-id pub-id-type="pmid">35697474</pub-id><pub-id pub-id-type="pmcid">PMC9195158</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Madabhavi</surname><given-names>IV</given-names></name><name name-style="western"><surname>Quy</surname><given-names>PN</given-names></name><name name-style="western"><surname>Govindagoudar</surname><given-names>MB</given-names></name></person-group><article-title>COVID-19 and coagulopathy</article-title><source>Clin Respir J</source><year>2021</year><volume>15</volume><issue>12</issue><fpage>1259</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1111/crj.13438</pub-id><pub-id pub-id-type="pmid">34399021</pub-id><pub-id pub-id-type="pmcid">PMC8444678</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Gonzalez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Ziccardi</surname><given-names>MR</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>MD</given-names></name></person-group><article-title>Virchow&#8217;s triad and the role of thrombosis in COVID-related stroke</article-title><source>Front Physiol</source><year>2021</year><volume>12</volume><fpage>769254</fpage><pub-id pub-id-type="doi">10.3389/fphys.2021.769254</pub-id><pub-id pub-id-type="pmid">34858214</pub-id><pub-id pub-id-type="pmcid">PMC8631516</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Violi</surname><given-names>F</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>L</given-names></name></person-group><article-title>Thromboembolism or atherothromboembolism in atrial fibrillation?</article-title><source>Circ Arrhythmia Electrophysiol</source><year>2012</year><volume>5</volume><issue>6</issue><fpage>1053</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1161/CIRCEP.112.979229</pub-id><pub-id pub-id-type="pmid">23250549</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimetbaum</surname><given-names>P</given-names></name><name name-style="western"><surname>Waks</surname><given-names>JW</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>ER</given-names></name><name name-style="western"><surname>Glotzer</surname><given-names>TV</given-names></name><name name-style="western"><surname>Passman</surname><given-names>RS</given-names></name></person-group><article-title>Role of atrial fibrillation burden in assessing thromboembolic risk</article-title><source>Circ Arrhythmia Electrophysiol</source><year>2014</year><volume>7</volume><issue>6</issue><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1161/CIRCEP.114.001356</pub-id><pub-id pub-id-type="pmid">25516580</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Healey</surname><given-names>JS</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Gold</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Subclinical atrial fibrillation and the risk of stroke</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>2</issue><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105575</pub-id><pub-id pub-id-type="pmid">22236222</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jame</surname><given-names>S</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>G</given-names></name></person-group><article-title>Stroke and thromboembolism prevention in atrial fibrillation</article-title><source>Heart</source><year>2020</year><volume>106</volume><issue>1</issue><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2019-314898</pub-id><pub-id pub-id-type="pmid">31533990</pub-id><pub-id pub-id-type="pmcid">PMC7881355</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>AI</given-names></name><name name-style="western"><surname>Baskett</surname><given-names>WI</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intracerebral hemorrhage and coronavirus disease 2019 in a cohort of 282,718 hospitalized patients</article-title><source>Neurocrit Care</source><year>2021</year><volume>36</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">34231186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12028-021-01297-y</pub-id><pub-id pub-id-type="pmcid">PMC8260011</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhamoon</surname><given-names>MS</given-names></name><name name-style="western"><surname>Thaler</surname><given-names>A</given-names></name><name name-style="western"><surname>Gururangan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Acute cerebrovascular events with COVID-19 infection</article-title><source>Stroke</source><year>2021</year><volume>52</volume><issue>1</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.031668</pub-id><pub-id pub-id-type="pmid">33280551</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahranifard</surname><given-names>B</given-names></name><name name-style="western"><surname>Mehdizadeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Hamidi</surname><given-names>A</given-names></name><etal/></person-group><article-title>A review of neuroradiological abnormalities in patients with coronavirus disease 2019 (COVID-19)</article-title><source>Neuroradiol J</source><year>2022</year><volume>35</volume><issue>1</issue><fpage>3</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1177/19714009211029177</pub-id><pub-id pub-id-type="pmid">34224248</pub-id><pub-id pub-id-type="pmcid">PMC8819585</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutsey</surname><given-names>PL</given-names></name><name name-style="western"><surname>Norby</surname><given-names>FL</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group><article-title>Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study</article-title><source>J Thromb Haemost</source><year>2018</year><volume>16</volume><issue>4</issue><fpage>670</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1111/jth.13974</pub-id><pub-id pub-id-type="pmid">29431904</pub-id><pub-id pub-id-type="pmcid">PMC5893387</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornestam</surname><given-names>B</given-names></name><name name-style="western"><surname>Adiels</surname><given-names>M</given-names></name><name name-style="western"><surname>Wai Giang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Atrial fibrillation and risk of venous thromboembolism: a Swedish Nationwide Registry Study</article-title><source>EP Europace</source><year>2021</year><volume>23</volume><issue>12</issue><fpage>1913</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1093/europace/euab180</pub-id><pub-id pub-id-type="pmid">34279622</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ptaszynska-Kopczynska</surname><given-names>K</given-names></name><name name-style="western"><surname>Kiluk</surname><given-names>I</given-names></name><name name-style="western"><surname>Sobkowicz</surname><given-names>B</given-names></name></person-group><article-title>Atrial fibrillation in patients with acute pulmonary embolism: clinical significance and impact on prognosis</article-title><source>Biomed Res Int</source><year>2019</year><volume>2019</volume><fpage>7846291</fpage><pub-id pub-id-type="doi">10.1155/2019/7846291</pub-id><pub-id pub-id-type="pmid">31531368</pub-id><pub-id pub-id-type="pmcid">PMC6720355</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bashir</surname><given-names>M</given-names></name><name name-style="western"><surname>Asher</surname><given-names>CR</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Right atrial spontaneous echo contrast and thrombi in atrial fibrillation: a transesophageal echocardiography study</article-title><source>J Am Soc Echocardiogr</source><year>2001</year><volume>14</volume><issue>2</issue><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1067/mje.2001.108668</pub-id><pub-id pub-id-type="pmid">11174446</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozer</surname><given-names>O</given-names></name><name name-style="western"><surname>Sari</surname><given-names>I</given-names></name><name name-style="western"><surname>Davutoglu</surname><given-names>V</given-names></name></person-group><article-title>Right atrial appendage: forgotten part of the heart in atrial fibrillation</article-title><source>Clin Appl Thromb Hemost</source><year>2010</year><volume>16</volume><issue>2</issue><fpage>218</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1177/1076029608323088</pub-id><pub-id pub-id-type="pmid">18840628</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aberg</surname><given-names>H</given-names></name></person-group><article-title>Atrial fibrillation: I. A study of atrial thrombosis and systemic embolism in a necropsy material</article-title><source>Acta Med Scand</source><year>1969</year><volume>185</volume><issue>1&#8211;6</issue><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">5808636</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gul</surname><given-names>MH</given-names></name><name name-style="western"><surname>Htun</surname><given-names>ZM</given-names></name><name name-style="western"><surname>de Jesus Perez</surname><given-names>V</given-names></name><etal/></person-group><article-title>Predictors and outcomes of acute pulmonary embolism in COVID-19; insights from US National COVID cohort collaborative</article-title><source>Respir Res</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/s12931-023-02369-7</pub-id><pub-id pub-id-type="pmid">36810085</pub-id><pub-id pub-id-type="pmcid">PMC9942071</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malas</surname><given-names>MB</given-names></name><name name-style="western"><surname>Naazie</surname><given-names>IN</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>N</given-names></name><etal/></person-group><article-title>Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis</article-title><source>EClinicalMedicine</source><year>2020</year><volume>29</volume><fpage>100639</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100639</pub-id><pub-id pub-id-type="pmid">33251499</pub-id><pub-id pub-id-type="pmcid">PMC7679115</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barra</surname><given-names>SNC</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>LV</given-names></name><name name-style="western"><surname>Provid&#234;ncia</surname><given-names>R</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>A</given-names></name><name name-style="western"><surname>Leit&#227;o Marques</surname><given-names>A</given-names></name></person-group><article-title>Atrial fibrillation in acute pulmonary embolism: prognostic considerations</article-title><source>Emerg Med J</source><year>2014</year><volume>31</volume><issue>4</issue><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1136/emermed-2012-202089</pub-id><pub-id pub-id-type="pmid">23349355</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulsalam</surname><given-names>MA</given-names></name><name name-style="western"><surname>Elganainy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Abdulsalam</surname><given-names>AJ</given-names></name></person-group><article-title>Pulmonary embolism causing atrial fibrillation with slow ventricular response: a case report</article-title><source>BMC Cardiovasc Disord</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s12872-019-1081-8</pub-id><pub-id pub-id-type="pmid">31035932</pub-id><pub-id pub-id-type="pmcid">PMC6489251</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YG</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YY</given-names></name><name name-style="western"><surname>Han</surname><given-names>K-D</given-names></name><etal/></person-group><article-title>Atrial fibrillation is associated with increased risk of lethal ventricular arrhythmias</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>18111</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-97335-y</pub-id><pub-id pub-id-type="pmid">34518592</pub-id><pub-id pub-id-type="pmcid">PMC8438063</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarrias</surname><given-names>A</given-names></name><name name-style="western"><surname>Villuendas</surname><given-names>R</given-names></name><name name-style="western"><surname>Bisbal</surname><given-names>F</given-names></name><etal/></person-group><article-title>From atrial fibrillation to ventricular fibrillation and back</article-title><source>Circulation</source><year>2015</year><volume>132</volume><issue>21</issue><fpage>2035</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018891</pub-id><pub-id pub-id-type="pmid">26596979</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingul</surname><given-names>CB</given-names></name><name name-style="western"><surname>Grimsmo</surname><given-names>J</given-names></name><name name-style="western"><surname>Mecinaj</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardiac dysfunction and arrhythmias 3 months after hospitalization for COVID-19</article-title><source>J Am Heart Assoc</source><year>2022</year><volume>11</volume><issue>3</issue><fpage>e023473</fpage><pub-id pub-id-type="doi">10.1161/JAHA.121.023473</pub-id><pub-id pub-id-type="pmid">35048715</pub-id><pub-id pub-id-type="pmcid">PMC9238505</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callans</surname><given-names>DJ</given-names></name></person-group><article-title>Premature ventricular contraction-induced cardiomyopathy</article-title><source>Arrhythm Electrophysiol Rev</source><year>2017</year><volume>6</volume><issue>4</issue><fpage>153</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.15420/aer.2017/6.4/EO1</pub-id><pub-id pub-id-type="pmid">29326827</pub-id><pub-id pub-id-type="pmcid">PMC5739884</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeremiah</surname><given-names>B</given-names></name><name name-style="western"><surname>Lubis</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>H</given-names></name></person-group><article-title>C64. New ONSET PVC bigeminy post Covid-19 infection: another covid-cardiac related problem</article-title><source>Eur Heart J Suppl.</source><year>2021</year><volume>23</volume><issue>Suppl F</issue><fpage>suab125.063</fpage><pub-id pub-id-type="doi">10.1093/eurheartjsupp/suab125.063</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammadyari</surname><given-names>E</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>I</given-names></name><name name-style="western"><surname>Mohammadyari</surname><given-names>A</given-names></name><name name-style="western"><surname>Tavan</surname><given-names>H</given-names></name><name name-style="western"><surname>Norozi</surname><given-names>S</given-names></name></person-group><article-title>The frequency of arrhythmias in COVID-19 patients, a study in the Shahid Mostafa Khomeini Hospital of Ilam from March to August 2020</article-title><source>New Microbes New Infect</source><year>2021</year><volume>41</volume><fpage>100867</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2021.100867</pub-id><pub-id pub-id-type="pmid">33758669</pub-id><pub-id pub-id-type="pmcid">PMC7972823</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coromilas</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kochav</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldenthal</surname><given-names>I</given-names></name><etal/></person-group><article-title>Worldwide survey of COVID-19-associated arrhythmias</article-title><source>Circ Arrhythm Electrophysiol</source><year>2021</year><volume>14</volume><issue>3</issue><fpage>e009458</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.120.009458</pub-id><pub-id pub-id-type="pmid">33554620</pub-id><pub-id pub-id-type="pmcid">PMC7982128</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><name name-style="western"><surname>Namazi</surname><given-names>A</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cardiac arrhythmias in hospitalized patients with COVID-19: a prospective observational study in the western United States</article-title><source>PLoS ONE</source><year>2021</year><volume>15</volume><issue>12</issue><fpage>e0244533</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244533</pub-id><pub-id pub-id-type="pmcid">PMC7769280</pub-id><pub-id pub-id-type="pmid">33370347</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peretto</surname><given-names>G</given-names></name><name name-style="western"><surname>Sala</surname><given-names>S</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>75</volume><issue>9</issue><fpage>1046</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.01.036</pub-id><pub-id pub-id-type="pmid">32138965</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitacchione</surname><given-names>G</given-names></name><name name-style="western"><surname>Schiavone</surname><given-names>M</given-names></name><name name-style="western"><surname>Gasperetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Forleo</surname><given-names>GB</given-names></name></person-group><article-title>Ventricular tachycardia storm management in a COVID-19 patient: a case report</article-title><source>Eur Heart J Case Rep</source><year>2020</year><volume>4</volume><issue>FI1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytaa217</pub-id><pub-id pub-id-type="pmid">33089046</pub-id><pub-id pub-id-type="pmcid">PMC7337657</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Shariff</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>V</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>C</given-names></name><name name-style="western"><surname>Deshmukh</surname><given-names>A</given-names></name></person-group><article-title>Atrial fibrillation after vaccination for COVID-19: analysis of the vaccine adverse event reporting system</article-title><source>J Interv Card Electrophysiol</source><year>2022</year><volume>65</volume><issue>1</issue><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1007/s10840-022-01263-4</pub-id><pub-id pub-id-type="pmid">35674855</pub-id><pub-id pub-id-type="pmcid">PMC9175153</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abutaleb</surname><given-names>MH</given-names></name><name name-style="western"><surname>Makeen</surname><given-names>HA</given-names></name><name name-style="western"><surname>Meraya</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Risks of cardiac arrhythmia associated with COVID-19 vaccination: a systematic review and meta-analysis</article-title><source>Vaccines (Basel)</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>112</fpage><pub-id pub-id-type="doi">10.3390/vaccines11010112</pub-id><pub-id pub-id-type="pmid">36679957</pub-id><pub-id pub-id-type="pmcid">PMC9862670</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>CT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CW</given-names></name></person-group><article-title>Atrial fibrillation after mRNA-1273 SARS-CoV-2 vaccination: case report with literature review</article-title><source>Risk Manag Healthc Policy</source><year>2023</year><volume>16</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.2147/RMHP.S402007</pub-id><pub-id pub-id-type="pmid">36798620</pub-id><pub-id pub-id-type="pmcid">PMC9926928</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theodorou</surname><given-names>A</given-names></name><name name-style="western"><surname>Bakola</surname><given-names>E</given-names></name><name name-style="western"><surname>Chondrogianni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Covid-vaccine-fear-induced paroxysmal atrial fibrillation causing multiple acute arterial infarctions: a case report</article-title><source>Ther Adv Neurol Disord</source><year>2022</year><volume>15</volume><fpage>17562864221094714</fpage><pub-id pub-id-type="doi">10.1177/17562864221094714</pub-id><pub-id pub-id-type="pmid">35498366</pub-id><pub-id pub-id-type="pmcid">PMC9047779</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>GA</given-names></name><name name-style="western"><surname>Azarbal</surname><given-names>JR</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hammel</surname><given-names>IS</given-names></name></person-group><article-title>Abstract 10638: the effectiveness of Covid 19 vaccines against new onset atrial fibrillation in hospitalized Covid 19 patients</article-title><source>Circulation</source><year>2022</year><volume>146</volume><issue>Suppl_1</issue><fpage>A10638</fpage><lpage>A10638</lpage></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Molecular and cellular mechanisms of atrial&#160;fibrosis in atrial&#160;fibrillation</article-title><source>JACC Clin Electrophysiol</source><year>2017</year><volume>3</volume><issue>5</issue><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.jacep.2017.03.002</pub-id><pub-id pub-id-type="pmid">29759598</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burstein</surname><given-names>B</given-names></name><name name-style="western"><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><issue>8</issue><fpage>802</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.09.064</pub-id><pub-id pub-id-type="pmid">18294563</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ordog</surname><given-names>B</given-names></name><etal/></person-group><article-title>Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><issue>5</issue><fpage>836</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305326</pub-id><pub-id pub-id-type="pmid">25608527</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thum</surname><given-names>T</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C</given-names></name><name name-style="western"><surname>Fiedler</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts</article-title><source>Nature</source><year>2008</year><volume>456</volume><issue>7224</issue><fpage>980</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1038/nature07511</pub-id><pub-id pub-id-type="pmid">19043405</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Shamhart</surname><given-names>PE</given-names></name><name name-style="western"><surname>Naugle</surname><given-names>JE</given-names></name><name name-style="western"><surname>Meszaros</surname><given-names>JG</given-names></name></person-group><article-title>Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase C&#948; and intracellular calcium in adult rat cardiac fibroblasts</article-title><source>Hypertension</source><year>2008</year><volume>51</volume><issue>3</issue><fpage>704</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.107.098459</pub-id><pub-id pub-id-type="pmid">18195168</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasquez</surname><given-names>C</given-names></name><name name-style="western"><surname>Mohandas</surname><given-names>P</given-names></name><name name-style="western"><surname>Louie</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Enhanced fibroblast-myocyte interactions in response to cardiac injury</article-title><source>Circ Res</source><year>2010</year><volume>107</volume><issue>8</issue><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.227421</pub-id><pub-id pub-id-type="pmid">20705922</pub-id><pub-id pub-id-type="pmcid">PMC2993566</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation</article-title><source>Cardiovasc Res</source><year>2011</year><volume>89</volume><issue>4</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq329</pub-id><pub-id pub-id-type="pmid">20962103</pub-id><pub-id pub-id-type="pmcid">PMC3039247</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlochiver</surname><given-names>S</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>V</given-names></name><name name-style="western"><surname>Vikstrom</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers</article-title><source>Biophys J</source><year>2008</year><volume>95</volume><issue>9</issue><fpage>4469</fpage><lpage>4480</lpage><pub-id pub-id-type="doi">10.1529/biophysj.108.136473</pub-id><pub-id pub-id-type="pmid">18658226</pub-id><pub-id pub-id-type="pmcid">PMC2567962</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roell</surname><given-names>W</given-names></name><name name-style="western"><surname>Lewalter</surname><given-names>T</given-names></name><name name-style="western"><surname>Sasse</surname><given-names>P</given-names></name><etal/></person-group><article-title>Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia</article-title><source>Nature</source><year>2007</year><volume>450</volume><issue>7171</issue><fpage>819</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1038/nature06321</pub-id><pub-id pub-id-type="pmid">18064002</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travers</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>FA</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>J</given-names></name><name name-style="western"><surname>Yutzey</surname><given-names>KE</given-names></name><name name-style="western"><surname>Blaxall</surname><given-names>BC</given-names></name></person-group><article-title>Cardiac fibrosis</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><issue>6</issue><fpage>1021</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306565</pub-id><pub-id pub-id-type="pmid">26987915</pub-id><pub-id pub-id-type="pmcid">PMC4800485</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Akazawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Tamagawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cardiac mast cells cause atrial fibrillation through PDGF-A&#8211;mediated fibrosis in pressure-overloaded mouse hearts</article-title><source>J Clin Investig</source><year>2010</year><volume>120</volume><issue>1</issue><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1172/JCI39942</pub-id><pub-id pub-id-type="pmid">20038802</pub-id><pub-id pub-id-type="pmcid">PMC2798688</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cardiovascular changes in patients with COVID-19 from Wuhan, China</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>7</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.00150</pub-id><pub-id pub-id-type="pmid">33102532</pub-id><pub-id pub-id-type="pmcid">PMC7498715</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>KT</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ahokas</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gerling</surname><given-names>IC</given-names></name></person-group><article-title>Myofibroblast-mediated mechanisms of pathological remodelling of the heart</article-title><source>Nat Rev Cardiol</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/nrcardio.2012.158</pub-id><pub-id pub-id-type="pmid">23207731</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosker</surname><given-names>C</given-names></name><name name-style="western"><surname>Salvarani</surname><given-names>N</given-names></name><name name-style="western"><surname>Schmutz</surname><given-names>S</given-names></name><name name-style="western"><surname>Grand</surname><given-names>T</given-names></name><name name-style="western"><surname>Rohr</surname><given-names>S</given-names></name></person-group><article-title>Abolishing myofibroblast arrhythmogeneicity by pharmacological ablation of &#945;-smooth muscle actin containing stress fibers</article-title><source>Circ Res</source><year>2011</year><volume>109</volume><issue>10</issue><fpage>1120</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.244798</pub-id><pub-id pub-id-type="pmid">21921266</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Nattel</surname><given-names>S</given-names></name></person-group><article-title>Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation</article-title><source>Cardiovasc Res</source><year>2010</year><volume>89</volume><issue>4</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq329</pub-id><pub-id pub-id-type="pmid">20962103</pub-id><pub-id pub-id-type="pmcid">PMC3039247</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>CS</given-names></name><name name-style="western"><surname>Pan</surname><given-names>CH</given-names></name></person-group><article-title>Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation</article-title><source>Cell Mol Life Sci</source><year>2008</year><volume>65</volume><issue>10</issue><fpage>1489</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1007/s00018-008-7408-8</pub-id><pub-id pub-id-type="pmid">18322650</pub-id><pub-id pub-id-type="pmcid">PMC11131653</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YY</given-names></name><name name-style="western"><surname>McTiernan</surname><given-names>CF</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>AM</given-names></name></person-group><article-title>Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells</article-title><source>Cardiovasc Res</source><year>1999</year><volume>42</volume><issue>1</issue><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(98)00297-1</pub-id><pub-id pub-id-type="pmid">10435007</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siwik</surname><given-names>DA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>DL</given-names></name><name name-style="western"><surname>Colucci</surname><given-names>WS</given-names></name></person-group><article-title>Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro</article-title><source>Circ Res</source><year>2000</year><volume>86</volume><issue>12</issue><fpage>1259</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1161/01.RES.86.12.1259</pub-id><pub-id pub-id-type="pmid">10864917</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murdoch</surname><given-names>CE</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cave</surname><given-names>AC</given-names></name><name name-style="western"><surname>Shah</surname><given-names>AM</given-names></name></person-group><article-title>NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure</article-title><source>Cardiovasc Res</source><year>2006</year><volume>71</volume><issue>2</issue><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2006.03.016</pub-id><pub-id pub-id-type="pmid">16631149</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siwik</surname><given-names>DA</given-names></name><name name-style="western"><surname>Colucci</surname><given-names>WS</given-names></name></person-group><article-title>Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium</article-title><source>Heart Fail Rev</source><year>2004</year><volume>9</volume><issue>1</issue><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1023/B:HREV.0000011393.40674.13</pub-id><pub-id pub-id-type="pmid">14739767</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YY</given-names></name><name name-style="western"><surname>Feng</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Kadokami</surname><given-names>T</given-names></name><etal/></person-group><article-title>Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><issue>23</issue><fpage>12746</fpage><lpage>12751</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.23.12746</pub-id><pub-id pub-id-type="pmid">11070088</pub-id><pub-id pub-id-type="pmcid">PMC18835</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>R</given-names></name></person-group><article-title>Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2007</year><volume>47</volume><issue>1</issue><fpage>211</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.47.120505.105230</pub-id><pub-id pub-id-type="pmid">17129183</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siwik</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Colucci</surname><given-names>WS</given-names></name></person-group><article-title>Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts</article-title><source>Am J Physiol Cell Physiol</source><year>2001</year><volume>280</volume><issue>1</issue><fpage>C53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.2001.280.1.C53</pub-id><pub-id pub-id-type="pmid">11121376</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yabluchanskiy</surname><given-names>A</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hall</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>ML</given-names></name></person-group><article-title>Matrix metalloproteinase-9: many shades of function in cardiovascular disease</article-title><source>Physiology (Bethesda)</source><year>2013</year><volume>28</volume><issue>6</issue><fpage>391</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">24186934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physiol.00029.2013</pub-id><pub-id pub-id-type="pmcid">PMC3858212</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation</article-title><source>Zhonghua Yi Xue Za Zhi</source><year>2005</year><volume>85</volume><issue>1</issue><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">15808077</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Niida</surname><given-names>S</given-names></name><name name-style="western"><surname>Dote</surname><given-names>K</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><issue>5</issue><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.08.060</pub-id><pub-id pub-id-type="pmid">14998623</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nath</surname><given-names>D</given-names></name><name name-style="western"><surname>Slocombe</surname><given-names>PM</given-names></name><name name-style="western"><surname>Webster</surname><given-names>A</given-names></name><etal/></person-group><article-title>Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1)integrin, leading to a marked induction of fibroblast cell motility</article-title><source>J Cell Sci</source><year>2000</year><volume>113</volume><issue>Pt 12</issue><fpage>2319</fpage><lpage>2328</lpage><pub-id pub-id-type="doi">10.1242/jcs.113.12.2319</pub-id><pub-id pub-id-type="pmid">10825303</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>B</given-names></name><name name-style="western"><surname>Price</surname><given-names>RL</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Left ventricular hypertrophy in ascending aortic stenosis mice</article-title><source>Circulation</source><year>2000</year><volume>101</volume><issue>24</issue><fpage>2854</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.24.2854</pub-id><pub-id pub-id-type="pmid">10859293</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peschon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Slack</surname><given-names>JL</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P</given-names></name><etal/></person-group><article-title>An essential role for ectodomain shedding in mammalian development</article-title><source>Science</source><year>1998</year><volume>282</volume><issue>5392</issue><fpage>1281</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1126/science.282.5392.1281</pub-id><pub-id pub-id-type="pmid">9812885</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arndt</surname><given-names>M</given-names></name><name name-style="western"><surname>Lendeckel</surname><given-names>U</given-names></name><name name-style="western"><surname>R&#246;cken</surname><given-names>C</given-names></name><etal/></person-group><article-title>Altered expression of ADAMs (<italic toggle="yes">A</italic>
<italic toggle="yes">D</italic>isintegrin <italic toggle="yes">A</italic>nd <italic toggle="yes">M</italic>etalloproteinase) in fibrillating human atria</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>6</issue><fpage>720</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1161/hc0602.103639</pub-id><pub-id pub-id-type="pmid">11839628</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>